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2.1 Colorectal Cancer 
Colorectal cancer also known as bowel cancer is characterized by the uncontrolled growth 
of abnormal cells inside the colon and or rectum. The colon and rectum are parts of the 
digestive system also called the gastrointestinal or GI system. The colon is the site where 
water and salt from solid wastes are extracted before they are eliminated from the body. It is 
the longest part of large intestine and is approximately 1-1.5 m long. It is divided into 4 
sections. The first section called the ascending colon begins where the small intestine 
attaches to the colon and extends upward on the right side of a person‟s abdomen. The 
second section is called the transverse colon as it crosses the body from the right to the left 
side. The third section, the descending colon, continues downward on the left side. The 
fourth section which is S shaped is known as the sigmoid colon. The sigmoid colon joins the 
rectum, which is the temporary storage place for the feces and is approximately 12-15 cm in 
length. The rectum in turn joins the anus. Histologically the colon and rectum wall 
comprises four distinct layers: mucosa, sub mucosa, muscle (muscularis propria) and serosa. 
 
The most common type of colorectal cancer cell is adenocarcinoma which accounts 
for 95% of cases. Other, rarer types include lymphoma and squamous cell carcinoma. 
Adenocarcinoma is a malignant epithelial tumor, originating from glandular epithelium of 
the colorectal mucosa. Colorectal cancer usually develops slowly over a period of many 
years. Before a true cancer develops, it usually begins as a noncancerous polyp, which may 
eventually change into colorectal cancer. A polyp is a growth of tissue that develops on the 
lining of the colon or rectum. Certain kinds of polyps, called adenomatous polyps or 
adenomas (benign neoplasm) are most likely to become cancers, although majority of 
adenomas never develop into cancer. Once cancer forms in the large intestine, in time it can 
grow through the lining and into the wall of the colon or rectum. Cancers that have invaded 
the wall can also penetrate blood vessels or lymph vessels. Cancer cells typically spread 
first into nearby lymph nodes and can also be carried in blood vessels to the liver or lungs, 
or can spread in the abdominal cavity and to other areas. The extent to which a colorectal 
cancer has spread is described as its stage. Tumors that have not yet begun to invade the 
wall of the colon or rectum are called carcinomas in situ, and are not counted in cancer 
statistics. 
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Figure 1: Normal colon and rectum. 
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Table1: TNM staging for CRC 
 
AJCC 
Stage 
TNM 
stage 
TNM stage criteria for colorectal 
cancer 
Stage 0 Tis N0 M0 Tis: Tumour confined to mucosa; cancer-in-situ 
Stage I T1 N0 M0 T1: Tumour invades submucosa 
Stage I T2 N0 M0 T2: Tumour invades muscularis propria 
Stage II-A T3 N0 M0 T3: Tumour invades subserosa or beyond 
(without other organs involved) 
Stage II-B T4 N0 M0 T4: Tumour invades adjacent organs or 
perforates the visceral peritoneum 
Stage III-A T1-2 N1 
M0 
N1: Metastasis to 1 to 3 regional lymph nodes. 
T1 or T2. 
Stage III-B T3-4 N1 
M0 
N1: Metastasis to 1 to 3 regional lymph nodes. 
T3 or T4. 
Stage III-C any T, N2 
M0 
N2: Metastasis to 4 or more regional lymph 
nodes. Any T. 
Stage IV any T, any 
N, M1 
M1: Distant metastases present. Any T, any N. 
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There is good morphological and molecular genetic evidence that colon carcinoma develops 
through several precursor stages. The histological progression of colorectal cancer from 
adenoma to carcinoma is now recognized as the process through which most colorectal 
carcinomas develop and was first described by Morson and colleagues (Muto et al., 1975) 
and the genetic pathway which parallels this transition has been suggested by Fearon, 
Vogelstein, Bodmer and others (Fearon and Vogelstein, 1990). Histological evidence of 
dysplasia is usually taken as the first recognizable step in the adenoma-carcinoma sequence. 
Small areas of epithelium with irregular glandular architecture termed aberrant crypt foci 
(ACF) have been reported to harbor mutations in APC, K-ras and TP53 (Jen et al. 1994). 
However, the relationship between aberrant crypt foci and adenomas is still not clear. 
Progression of an adenoma is more likely with increased size, severe features of dysplasia 
villous rather than tubular architecture. Finally overt features of carcinoma are characterized 
by local invasion and eventual metastasis. 
 
2.2 Epidemiology of colorectal cancer       
Colorectal cancer (CRC) is one of the most common cancers in developed countries. 
Colorectal cancer  is the third most commonly reported cancer in the world, with over one 
million cases occurring annually (Parkin et al., 2005; Garcia et al., 2007). More than 
600,000 people die every year from the disease worldwide (Garcia et al., 2007). It is the 
second most common cause of death from cancer across all cancer types in men and women 
in Europe (Ferlay et al., 2007). In 2008, colorectal cancer ranked 3rd among the most 
incident forms of non-skin cancer in the U.S. for both men and women (Jemal et al., 2008). 
Approximately 146,970 new cases of large bowel cancer are diagnosed each year in US, of 
which 106,100 are colon and the remainder rectal cancers (Jemal et al., 2009).Annually, 
approximately 49,920 Americans die of CRC, accounting for approximately 9% of all 
cancer deaths. Over one-third (329,529 cases -36%) of new cases of colorectal cancer occur 
outside industrialized countries, the standard myth of colorectal cancer being a disease 
restricted to western countries needs to be dispelled. The incidence of this malignancy 
shows considerable variation among racially or ethnically defined populations in multi 
racial/ethnic countries. It is of potentially considerable significance that the high rates are to 
be found in a variety of population groups including Blacks in Detroit (34.9 per 100,000), 
Los Angeles (34.8), San Francisco (33.8), Atlanta (32.4) and New Orleans (31.4), Japanese 
and Whites in Hawaii (34.4 and 32.7,respectively) and non-Maori in New Zealand (31.2). 
Incidence rates (per 100,000) reported for Blacks, Whites, Asian/Pacific Islanders, 
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American Indian/Alaskan and Hispanics are 50.1, 42.9, 38.2, 28.6 and 28.4 respectively       
( Howe et al., 2001). World-wide, in men the lowest incidence rates are found in a variety of 
population groups in the non-industrialized countries with the lowest rate reported in Setif, 
Algeria (0.4 per 100,000). In women, the group of highest incidence rates includes 
population groups in New Zealand and North America with the lowest rates recorded in 
Algeria and India. In each sex, a number of low rate regions are found in India (Parkin et 
al., 1997). 
 
 
2.3 Risk factors for colorectal cancer 
Epidemiologic studies have revealed a number of risk factors for colorectal cancer including 
age, family history of colon cancer or inflammatory bowel disease, smoking, alcohol 
consumption, obesity, diet etc. 
 
 
2.3.1 Age 
Colorectal cancer is most commonly found in those aged 50 years and over. The SEER, 
2009 (Surveillance Epidemiology and End Results) Cancer Statistics Review found that 
between 1998 and 2002, less than 15% of new colorectal cancer cases occurred among those 
less than 54 years of age, 17% occurred among those between 55 and 64 years old, 26.3% 
occurred among those between 65 and 74 years old, 29.2% occurred among those between 
75 and 84 years old, and 12.6% of new cases were among those over the age of 85 (SEER, 
2009). When colon and rectal cancers are considered separately, over 50% of new cases in 
each group still occur among those 65 to 84 years old (SEER, 2009). 
 
 
2.3.2 Sex 
Men are more likely than women to develop colorectal cancer. The incidence rate of 
colorectal cancer between 2000 and 2004 was 69.2 per 100,000 population among men and 
45.8 per 100,000 populations among women (Jemal et al., 2008). The SEER, 2009 Review 
found similar incidence rates between 1998 and 2002. Additionally, the breakdown between 
the rates of colon and rectal cancers were given separately in that report. The incidence of 
colon cancer was 43.4 per 100,000 among men and 34.5 per 100,000 among women and the 
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incidence of rectal cancer was 18.5 per 100,000 and 11.7 per 100,000 for men and women 
respectively. 
 
2.3.3 Race 
African Americans have the highest incidence rates of colorectal cancer. Between year 2000 
and 2004 the number of new cases of colorectal cancer per 100,000 population among men 
was 60.4 among whites, 72.6 among African Americans, 49.7 among Asian Americans and 
Pacific Islanders, 42.1 among American Indians and Alaska Natives and 47.5 among 
Hispanics and Latinos ( Jemal   et al., 2008). Among women during the same time period, 
the numbers of new cases of colorectal cancer per 100,000 populations were 44.0 among 
whites, 55.0 among African Americans, 35.3 among Asian Americans and Pacific Islanders, 
39.6 among American Indians and Alaska Natives, and 32.9 among Hispanics and Latinos 
(Jemal et al., 2008). 
 
2.3.4 Physical Activity 
Studies have also found that physical activity is associated with lower risk of colorectal 
cancer. A meta-analysis published in 2004 found that among 47 studies that examined the 
association between colon and/or colorectal cancer and physical activity, physically active 
males had a lower risk of developing colon cancer regardless of specific type of activity 
(recreational or occupational) and regardless of the type of study (cohort or case-control) 
(Samad et al., 2005). The study found that women who participated in recreational physical 
activity also had a lower risk of developing colon cancer in both cohort and case-control 
studies but that occupational physical activity among women only showed a reduced risk for 
colon cancer among case-control studies. Additionally, this meta-analysis found no 
association between physical activity and risk of rectal cancer. Another study examined 
physical activity based on data from the European Prospective Investigation into Cancer and 
Nutrition (EPIC) (Friedenreich et al., 2006). A test for heterogeneity found no statistically 
significant difference in the results for men and women for overall physical activity and 
each type of physical activity (occupational, household, and recreational) in their association 
with colon and rectal cancers. Further analysis showed that physically active adults were at 
a reduced risk for colon cancer compared to inactive adults (RR = 0.78; 95% CI 0.59 – 1.03) 
with recreational activity being the most protective form of physical activity. This study also 
found that increased physical activity was not associated with a reduction in rectal cancer 
risk. While this study showed no difference in the association between physical activity and 
  REVIEW OF LITERATURE 
13 
 
colon cancer risk among men and women, other studies have found that physical activity is 
not associated or only modestly associated with reduced risk of colon cancer in women 
(Calton et al., 2006 ; Mai et al., 2007). The conflicting results of these studies are evidence 
that further research is needed to determine the true associations if any between physical 
activity and colon cancer risk. One aspect of physical activity that has not been considered 
in the majority of the studies is looking at physical activity and colorectal cancer risk is 
lifetime change in physical activity. A case-control study conducted at the German Cancer 
Research Center collected data about recreational and occupational physical activity at ages 
20, 30, 40, 50, and 60 years for each subject. The results of the study showed that the odds 
ratio was 0.26 (95% CI 0.08 – 0.84) for colon cancer risk for lifelong constantly high-
exercisers compared with lifelong non-exercisers (Steindorf et al., 2005). This study found 
no association between lifetime physical activity and risk of rectal cancer. Further analysis 
of lifetime physical activity patterns including type, frequency and duration will strengthen 
our understanding of the potential association between physical activity and colon cancer 
risk. 
 
2.3.5 Obesity 
Over the past 30 years the rates of obesity have increased dramatically. The prevalence 
actually doubled among adults aged 20 years and older between the years 1980 and 2002 
(Hedley et al., 2004). A recent study of the prevalence of obesity in the United States 
analyzed data from the National Health and Nutrition Examination Survey (NHANES) from 
2003 to 2004. The researchers used body mass index (BMI) the ratio of weight in kilograms 
to the square of height in meters in order to calculate rates of overweight and obesity. The 
World Health Organization has set forth a standard definition of each weight class based on 
BMI. The results of the study showed that based on these definitions in 2003-2004, 61.8% 
of adult women were considered overweight or obese. The prevalence of obesity (BMI of 
greater than 30 kg/m2) was 33.2% and extreme obesity (BMI of greater than 40 kg/m2) was 
6.9%. Non-Hispanic black women had the highest prevalence for all categories: overweight 
or obese, obese, and extremely obese at 81.6%, 53.9%, and 14.7% respectively (Hedley et 
al., 2004). These rates are alarming considering the increased risk of morbidity and 
mortality associated with a higher BMI (Hedley et al., 2004). 
A number of studies have shown that being overweight is associated with increased risk of 
colorectal cancer. A case-control study conducted by Caan  found that men who had a BMI 
in the highest quintile were almost 2 times as likely to develop colon cancer as men with a 
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BMI in the lowest quintile (OR = 1.96; 95% CI 1.50 – 2.57). Women with a BMI in the 
highest quintile were about 1.5 times as likely to develop colon cancer when compared to 
women with BMIs in the lowest quintile (OR = 1.45; 95% CI 1.08 – 1.94). The study also 
found that these associations were much stronger among younger men and women with a 
family history of colon cancer (Caan et al., 1998). Another study looking the association 
between BMI and colon cancer risk found that those with a BMI ≥ 30.0 kg/m2 had an 
increased risk of developing colon cancer compared to those with a normal BMI (OR = 
1.54; 95% CI 1.03 – 2.31). The study also found that those whose BMI increased by more 
than 10 kg/m
2
 between their 30s and the time of recruitment into the study had a higher risk 
of developing colon cancer than those whose BMI did not change as much (Nock et al.,  
2008). Obesity is an important risk factor to consider based on the recent trends in the U.S. 
If there is a strong association between BMI and colon cancer risk, then continually 
increasing obesity rates will only increase the incidence of colon cancer throughout the 
population. 
 
2.3.6 Smoking  
The large bowel has not historically been considered as a site where the risk of cancer is 
linked to cigarette smoking (IARC, 1986) although it has been suggested that it may be an 
independent risk factor which may be specifically associated with the early stages of 
colorectal epidemiology (Giovannucci et al., 1994). A more recent review of all 
epidemiological evidence has indicated the strength and consistency of this finding 
(Giovannucci, 2001). Giovannucci concluded that 21 out of 22 studies found that long-term, 
heavy cigarette smokers have a 2–3-fold elevated risk of colorectal adenoma (Giovannucci, 
2001). The risk of large adenomas, those who present a high risk of colorectal cancer within 
a relatively short time frame was elevated in smokers in all 12 studies which examined this 
association. The studies of smoking and colorectal cancer risk conducted earlier in the 
1950s through 1970s did not show consistently any association and led review groups to 
consider that based on the available evidence that there was no association demonstrated      
( IARC, 1986). However 27 studies in various countries, including the large majority of 
those that have been conducted in the past two decades, show a consistent association 
between tobacco use (essentially cigarette smoking) and colorectal cancer. In the US 15 of 
16 studies conducted after 1970 in middle-age men and elderly men and in the 1990s in 
women demonstrate such an association. Giovannucci considered that this temporal pattern 
is consistent with an induction period of three to four decades between exposure and the 
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development of clinical colorectal cancer (Giovannucci, 2001). Overall accumulating 
evidence much within the past decade strongly supports the addition of colorectal cancer to 
the list of tobacco associated malignancies. Such an association has biological plausibility 
since carcinogens from tobacco could reach the colorectal mucosa through either the 
alimentary tract or the circulatory system and then damage or alter expression of cancer-
related genes. It appears likely that up to one in five colorectal cancers in the US may be 
associated with such exposure. 
 
2.3.7 Dietary and nutritional practices 
For many years, a diet rich in vegetables and fruit has been associated with a reduced risk of 
colorectal cancer in many, but not all, observational studies (Steinmetz and Potter, 1991). 
The association between fruit and vegetable consumption and the incidence of colon and 
rectal cancers has been studied in two cohorts: the Nurses‟ Health Study (88,764 women) 
and the Health Professionals‟ Follow-up Study (47,325 men) (Michels et al., 2000). 
Assessment of the diet was completed during different calendar years in women and men, 
during which a total of 1,743,645 person-years of follow-up were accrued and 937 cases of 
colon cancer were identified. No association was found between colon cancer incidence and 
fruit and vegetable consumption. For women and men combined, a difference in fruit and 
vegetable consumption of one additional serving per day was associated with a co-variate-
adjusted RR of greater magnitude but lacking statistical significance (1.02; 95% CI, 0.98–
1.05) ( Steinmetz and Potter, 1991). This lack of association between consumption of 
vegetables and fruits and colorectal cancer risk contradicts a widely accepted relationship 
between nutritional practices and chronic disease risk. Another association under scrutiny is 
that between fat intake and colorectal cancer risk. Hitherto, there appeared to be consistent 
evidence from epidemiological studies that intake of dietary fat and meat is positively 
related to colorectal cancer risk: this evidence is obtained from ecological studies, animal 
experiments, and case-control and cohort studies. Many of these studies have failed to 
demonstrate that the association observed with fat intake is independent of energy intake. 
The report by Willett provided the best epidemiological evidence to date identifying 
increased meat consumption as a risk factor for colon cancer independently of its 
contribution to fat intake and total caloric intake (Willett et al., 1990). A recently published 
meta-analysis of 13 prospective studies looking at meat consumption and colorectal cancer 
risk has reported an increased risk (12–17%) with a daily increase of 100 g of all meat or 
red meat. The risk was higher (49%) with a daily increase of 25 g of processed meat 
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(Sandhu et al., 2001). Again in a second study published in parallel, high intake of 
carcinogenic compounds produced when meat is well-cooked at high temperatures has been 
associated with an increased risk of colorectal adenomas (Sinha et al., 2001). 
Among protective dietary factors, the original hypothesis of the effect of dietary fiber was 
based on a clinical/pathological observation and a hypothesized mechanism whereby 
increasing intake of dietary fiber increases fecal bulk and reduces transit time. The term 
„fiber‟ encompasses many components each of which has specific physiological functions. 
The commonest classification is into the insoluble, non-degradable constituents (mainly 
present in cereal fiber) and into soluble, degradable constituents like pectin and plant gums 
which are mainly present in fruits and vegetables. Epidemiological studies have reported 
differences in the effect of these components. For example Tuyns and Kune found a 
protective effect for total dietary fiber intake in case-control studies (Tuyns et al., 1987 and 
Kune et al., 1987) and the same was found in one prospective study (Heilbrun et al., 1986). 
However a large number of studies could find no such protective effect (Willett, 1990). The 
large majority of studies in humans found no protective effect of fiber from cereals but 
consistently found a protective effect of fiber from vegetable and perhaps fruit sources 
(Willett, 1990; Steinmetz and Potter, 1991) and dietary diversity has been shown to be an 
important element in this protection (Fernandez et al., 1996). This could conceivably reflect 
an association with other components of fruits and vegetables, with „fiber‟ intake acting 
merely as an indicator of consumption. Two randomized studies conducted in the US 
looking at dietary interventions and the risk of recurrent adenomatous polyps have revealed 
no protective effect on the recurrence rate of colorectal polyps. The dietary interventions in 
question were for the Polyp Prevention Trial (Schatzkin et al., 2000) to have either intensive 
counseling to follow a low-fat, high fiber, fruit and vegetable diet or to be given a brochure 
on healthy eating and for the Wheat Bran Fiber Study to have a high wheat bran fiber cereal 
supplement (13.5 g of fiber in 2/3 cup cereal per day) or low wheat bran fiber cereal 
supplement (2 g of fiber in 2/3 cup cereal per day). The latter study reports that increasing 
dietary fiber will not reduce the risk of developing colorectal cancer, however, praising the 
benefits of high fiber diets for the prevention of other chronic conditions. Possible 
explanations for the observed negative results in both studies may be a short follow-up 
period precluding the detection of cancerous lesions that require of longer time before 
emerging. A potential pathway for this protective association has been investigated in a 
novel epidemiological study design (Freedman et al., 1996). Cruciferous vegetable intake 
exhibited a significant inverse association with colorectal cancer risk (OR, 0.59; 95% CI, 
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0.34, 1.02). When tumors were characterized by p53 over expression (p53 positive) 
etiological heterogeneity was suggested for family history of colorectal cancer (OR, 0.39; 
95% CI, 0.16, 0.93), intake of cruciferous vegetables (test for trend, P = 0.12) and beef 
consumption (test for trend, P = 0.08). Cruciferous vegetable consumption exhibited a 
significant association when p53 positive cases were compared with controls (OR, 0.37; 
95% CI, 0.17, 0.82). When p53 negative cases were compared with controls a significant 
increase in risk was observed for family history of cancer (OR, 4.46; 95% CI, 2.36, 8.43) 
and beef consumption (OR, 3.17; 95% CI, 1.83, 11.28). The p53 (positive) dependent 
pathway was characterized by an inverse association with cruciferous vegetable intake and 
p53 independent tumors were characterized by family history and beef consumption 
(Freedman et al., 1996). 
 
2.3.8 Heredity and Medical History 
People who have a first-degree relative (parent, sibling, or offspring) who has had colorectal 
cancer have about twice the risk of developing the disease compared to individuals with no 
family history (Johns and Houslton, 2001; Butterworth et al, .2006).  The risk increases 
even further if the relative was diagnosed at a young age or if there is more than one 
affected relative (Johns and Houslston, 2001). About 20% of all colorectal cancer patients 
have a close relative who has been diagnosed with the disease (Lynch and de la Chapelle, 
2003). About 5%-10% of patients with colorectal cancer have an inherited genetic alteration 
that causes the cancer (Lynch and de la Chapelle, 2003).One such disorder is familial 
adenomatous polyposis (FAP); which causes hundreds or thousands of polyps to develop in 
the colon from a very young age. If these polyps are left untreated, that person has a very 
high risk of those polyps developing into cancer. Another genetic disorder that causes 
colorectal cancer is hereditary non-polyposis colorectal cancer (HNPCC) which accounts 
for 5%-8% of colorectal cancers (Heavey et al., 2004). Unlike FAP, HNPCC does not result 
in an excess number of polyps. According to Heavey, HNCPP “seems to accelerate the 
carcinogenic process through an increased mutation rate in microsatellite regions, which 
then affects other genes involved in cell cycling and proliferation” (Heavey et al., 2004). 
Someone with HNPCC has an 80% chance of developing colorectal cancer throughout his 
or her life. While other genetic mutations have been associated with increased colon cancer 
risk, those two (FAP and HNPCC) are the most common. While other factors also 
contribute to the development of colon cancer, understanding family history is an important 
first step in assessing an individual‟s risk. 
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2.3.8.1 A personal history of CRC, polyps, or chronic inflammatory bowel disease 
 People who have had colorectal cancer are more likely to develop new cancers in other 
areas of the colon and rectum, even if the first cancer has been completely removed. The 
risk of a second cancer is much greater if the first cancer was diagnosed at age 60 or 
younger. People who have had one or more adenomatous polyps have an increased risk of 
colorectal cancer. This is especially true if the polyps were large or if there was more than 
one (Schatzkin et al., 1994). People who have a chronic inflammatory bowel disease of 
significant duration and involving the entire bowel have an increased risk of developing 
colorectal cancer  (Bernstein et al., 2001) This includes conditions such as ulcerative colitis 
and Crohn disease in which the colon is inflamed over a long period of time. 
 
2.3.8.2 Diabetes 
Many studies have found an association between diabetes and increased risk of colorectal 
cancer in both men and women. (Giovannucci, 2007; Larsson et al., 2005) Adult onset 
(Type 2) diabetes, the most common type of diabetes, and colorectal cancer share similar 
risk factors, including physical inactivity and obesity. However, a positive association 
between diabetes and colorectal cancer has been found in studies that accounted for physical 
activity, body mass index, and waist circumference (Larsson et al., 2005). 
 
 
2.4 Molecular biology of CRC 
 
In 1990 Fearon and Vogelstein proposed a multistep model for colorectal carcinogenesis 
that has become widely cited (Fearon and Vogelstein, 1990). Their model is based on four 
principle points. First, colorectal tumors are clonal entities that arise as the result of the 
mutational activation of oncogenes as well as the inactivation of tumor suppressor genes. 
Second, at least four to five genes must be mutated to accomplish carcinogenesis. Third, the 
final accumulation of mutations does not have to happen in a specific order. There is an 
order in which these mutations tend to accumulate, but the total accumulation, not the 
sequential order, is the key event. Last, some tumor suppressor genes, when mutated, can 
produce the neoplastic phenotype even when in the heterozygous state-knock-out of both 
alleles is not always necessary. 
The two major pathways in CRC carcinogenesis are the chromosomal instability (CIN) and 
the microsatellite instability (MSI) pathways (Takayama et al., 2006). The discovery of the 
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molecular changes that occur in the chromosomal instability pathway has been the 
foundation behind the development of the adenoma- carcinoma sequence. Most familial and 
sporadic CRCs develop in pre-existing adenomatous polyps (Piepins and Sandler, 1994). 
The development of the precancerous adenomatous polyp and its subsequent malignant 
degeneration involve multiple allelic losses resulting in loss of heterozygosity (LOH). These 
allelic losses lead to dysfunctional tumor suppressor genes or aberrant activation of proto-
oncogenes (Robbins and Itzkowitz, 2002). The MIS pathway involves mutations in DNA 
mismatch repair (MMR) repair genes. The products of these genes are responsible for the 
recognition of DNA replication errors. Areas within the genome that contain tandem repeats 
of DNA sequences, also known as microsatellites, are particularly susceptible to replication 
errors. The occurrence of these replication errors within the coding sequence of genes 
responsible for cellular growth and regulatory functions can lead to malignant 
transformation (Radtke et al., 2006). Recently, other molecular pathways involved in 
colorectal tumorogenesis, such as the transforming growth factor (TFG)-β signaling 
pathway, have been identified. Additionally, various alterations in expression of genes 
involved in tumor angiogenesis, growth, and metastasis have been described. 
 
 
 
2.4.1 Chromosomal instability pathway 
 
2.4.1.1 APC/β-catenin 
One mutation known to occur early in the adenoma-carcinoma Sequence affects the 
adenomatous Polyposis coli (APC) tumor suppressor gene located on chromosome 5q21 
(Bodmer et al.,1987; Groden et al.,1991). Germ-line APC mutations give rise to familial 
adenomatous polyposis, an inherited cancer-predisposition syndrome in which more than 
100 adenomatous polyps can develop; in carriers of the mutant gene, the risk of colorectal 
cancer by the age of 40 years is almost 100% ( Kinzler andVogelstein, 2002 ; Lynch et al.,  
2008; Goss and Groden, 2000 ). The product of APC gene is a multifunctional protein with 
several domains that is known to interact with a number of other proteins including beta-
catenin, glycogen synthase kinase (GSK)3B, end binding protein(EB) 1,Bub Kinase and 
human homologue of  Drosophila discs large tumor suppressor protein (hDLG) ( Rubinfeld 
et al., 1996; Kaplan et al., 2001; Matsumine et al., 1996).  APC mutation or allelic losses of 
5q are observed in 40-80% of CRC (Vogelstein et al., 1988, Powell et al., 1992; Miyoshi et 
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al., 1992; Miyaki et al., 1994) and are found at similar frequency in adenomas (Vogelstein 
et al., 1988; Powell et al., 1992; Miyoshi et al., 1992; Miyaki et al., 1994; Jen et al., 1994). 
Interestingly although APC mutations occur at similar frequency at all stages of colonic 
tumor progression, allelic loss or loss of heterozygosity (LOH) has been shown to increase 
in frequency from earlier adenomas through to invasive carcinoma (Miyaki et al., 1994). 
Furthermore mutated APC has been demonstrated in adenomas as small as 0.5cm (Powell et 
al., 1992), reinforcing the belief that such mutations are involved earlier in adenoma-
carcinoma sequence. Finally about half of those tumors with wild type APC have been 
found to harbor beta catenin mutations (Morin et al., 1997; Sparks et al.,  1998) suggesting 
that these mutations can substituted for APC mutations in colorectal carcinogenesis. 
However it is intriguing that β-catenin mutations occur significantly more frequently in 
small adenomas (12.5 per cent) than in large adenomas (2.4 per cent) or invasive cancers 
(1.4 per cent) (Samowitz et al., 1999). This observation suggests that adenomas with β-
catenin mutations may be less likely to progress to invasive cancer. 
 
2.4.1.2 p53  
The p53 gene is the gene most frequently altered in human cancers (Caron and Soussi, 
1992). Located on the short arm of chromosome 17, p53 was initially implicated in 
colorectal cancer as a result of the frequent loss of 17p in allelic loss and cytogenetic studies 
(Baker et al., 1989; Fearon et al., 1987; Meling et al., 1993; Muleris et al., 1985). In brief 
p53 has been labeled the “guardian of the genome”  because of its ability to block cell 
proliferationin the presence DNA damage to stimulate DNA repair and to promote apoptotic 
cell death if repair is insufficient (Lane, 1992).The inactivation of the p53 pathway by 
mutation of  TP53 is the second key genetic step in colorectal cancer. In most tumors, the 
two TP53 alleles are inactivated, usually by a combination of a mis-sense mutation that 
inactivates the transcriptional activity of p53 and a 17p chromosomal deletion that 
eliminates the second TP53 allele (Kinzler and Vogelstein, 2002; Grady and Markowitz, 
2002; Fearon and Bommer, 2008; Baker et al., 1990). Wild-type p53 mediates cell-cycle 
arrest and a cell-death checkpoint, which can be activated by multiple cellular stresses 
(Vazquez et al., 2008). The inactivation of TP53 often coincides with the transition of large 
adenomas into invasive carcinomas (Baker et al., 1990). In many colorectal cancers with 
mismatch-repair defects, TP53 remains wild-type though in these cancers the activity of the 
p53 pathway is probably attenuated by mutations in the inducer of apoptosis (Kinzler and 
Vogelstein, 2002, Fearon and Bommer, 2008).Many reports on frequency of p53 mutations 
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in colorectal tumors have been based on the immuno-histochemical evidence of over 
expression, some have employed direct DNA sequencing and others have investigated 17p 
allelic loss. Thus it can be said that alteration in p53 or 17p allelic loss has been reported in 
4-26 % of adenomas (Vogelstein et al., 1988;  Scott et al., 1993; Rashid et al., 1999; 
Darmon et al., 1994; Ohue  et al., 1994; Yamaguchi et al., 1994; Kaklamanis et al., 1993) in 
approximately 50% of invasive foci within adenomatous polyps  (Ohue  et al., 1994; 
Yamaguchi et al., 1994) and in 50-75% of adenocarcinomas (Vogelstein et al., 1988; 
Hardingham et al., 1998;  Darmon et al., 1994;  Kaklamanis et al. 1993; Kaserer et al.,  
2000; Boland et al., 1995). This distribution has led to the belief that functional inactivation 
of p53 protein is associated with the transition from adenoma to carcinoma. 
 
2.4.1.3 K-ras 
A further genetic alteration believed to occur early in the adenoma-carcinoma sequence is 
an activating mutation of the oncogene K-ras. This oncogene, one of three of the ras gene 
family encodes a 21-kDa protein (ras p21) involved in signal transduction of regulatory 
pathways critical for normal proliferation and differentiation (Bos, 1989; Bourne et al., 
1990). It is a Guanosine 5‟- Triphosphate(GTP) binding protein located at the cytoplasmic 
aspect of cell membrane with intrinsic GTPase activity that is regulated by several other 
proteins (King, 2000). All known carcinogenic mutations of K-ras oncogene affect codons 
in the GTP-binding domain, decrease its GTPase activity and result in a constitutively active 
ras protein (King, 2000). 
Activating K-ras mutations occur in 35-42 per cent of colorectal carcinomas (Vogestein et 
al., 1988) and are observed at a similar frequency in large adenomas (Vogestein et al., 1988; 
Scott et al., 1993; Rashid et al., 1999). The relatively high frequency of ras mutated 
adenomas supports the hypothesis of this oncogene as an early participant in the adenoma-
carcinoma sequence. However as K-ras mutation is less common in small adenomas 
(Vogelstein et al., 1988; Scott et al., 1993; Rashid et al., 1999) it seems that while this 
alteration confers a growth advantage it is unlikely to be an initiating factor in colorectal 
tumorigenesis. 
 
2.4.1.4 DCC 
Located on chromosome 18, the primary role of the product of the deleted in colon cancer 
(DCC) gene is believed to be tumor suppression and possibly as an apoptosis substrate 
(Robbins and Itzkowitz, 2002). Approximately 70% of CRCs exhibit losses on chromosome 
  REVIEW OF LITERATURE 
22 
 
18 (Fearon and and Vogelstein, 1990). Several late steps in the adenocarcinoma sequence 
are linked to loss of DCC function. Recently the significance of DCC in colorectal 
carcinogenesis has been questioned. Other genetic loci involved in CRC development, such 
as SMAD2 and 4 have been identified near the DCC sequence on chromosome 18q  (Hahn 
et al., 1996; Eppert et al., 1996) . Loss of DCC may represent only a marker for deletion of 
adjacent tumor suppressor genes. Therefore the significance of DCC in colorectal 
tumorogenesis remains an area of debate and investigation.  
 
2.4.1.5BRAF 
Oncogenic mutations of BRAF, which activate the mitogen-activated protein kinase 
(MAPK) signaling pathway,occur in 13% of colorectal cancers (Davies et al., 2002). BRAF 
mutations signal BRAF serine–threonine kinase activity which further drives the MAPK 
signaling cascade (Rajagopalan et al., 2002; Siena et al., 2009).  BRAF mutations are 
detectable even in small polyps, (Nosho et al., 2008) and as compared with RAS mutations; 
they are more common in hyperplastic polyps, serrated adenomas, and proximal colon 
cancers, particularly in those with the CIMP phenotype. 
 
2.4.1.6 PI3K 
One third of colorectal cancers bear activating somatic mutations in PI3KCA, which 
encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K) (Samuels et al., 2004). 
Less common genetic alterations that may substitute forPI3KCAmutations include loss of 
PTEN, an inhibitor of PI3K signaling, as well as amplification of insulin receptor substrate 
2(IRS2), an upstream activator of PI3K signaling, and co-amplification of AKT and PAK4 
which are downstream mediators of PI3K signaling (Parsons et al., 2005). 
 
2.4.2 Microsatellite instability Pathway  
Recently an alternative pathway of tumorigenesis for a subset of colorectal tumors has been 
proposed, characterized by the presence of MSI. Microsatellites are a type of DNA that 
consists of tandem repeats usually between one and five base pairs, repeated many times 
(Wheeler and Bodmer, 2000). Hundreds of thousands of microsatellites are found 
interspersed throughout the human genome and are particularly prone to errors during DNA 
replication. Such errors are usually repaired by mismatch repair (MMR) proteins but in the 
absence of competent MMR function microsatellite errors accumulate (Wheeler and 
Bodmer, 2000).When these errors are sufficiently frequent the terms MSI or replication 
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error positive (RER
+
) is applied. More recently tumours showing MSI have been further 
classified into those exhibiting low and high levels of instability (MSI-L and MSI-H 
respectively) (Dietmaier et al., 1997). When a cell is MMR deficient it is not only 
microsatellites that are at risk of replication error but all nucleotide repeat sequences, 
including those in coding regions of key regulatory genes. Thus  MSI can be interpreted as a 
marker for a state of hyper mutability or a „mutator phenotype (Parsons et al., 1993; Loeb,  
1991).   
MSI is observed in almost all adenocarcinomas from patients with hereditary non-polyposis 
colorectal cancer (HNPCC) (Aaltonen et al., 1994 a, Aaltonen et al., 1994 b; Konish et al., 
1996) and occurs in 10- 15 percent of sporadic colorectal cancers (Ionov et al., 1993; 
Aaltonen et al., 1994 a, Aaltonen et al., 1994 b, Konish et al., 1996, Thibodeau et al., 1993, 
Jass et al., 1998; Lothe et al., 1993). HNPCC is an autosomal dominantly inherited 
condition that accounts for approximately 5% of all cases of colorectal cancer (Wheeler and 
Bodmer, 2000). It is characterized by relatively small numbers of adenomas, the 
development of colorectal cancer at an early age, a predominance of tumors in the proximal 
colon and is sometimes associated with extra colonic tumors, such as gastric and 
endometrial cancer (Wheeler and Bodmer, 2000; Markowitz and Winawer, 1997 ).The 
presence of MSI-H in sporadic colorectal cancer and HNPCC correlates significantly with a 
number of clinical and pathological features including proximal location (Ionov et al.,  
1993; Aaltonen et al., 1994 a;  Thibodeau et al., 1993), diploid DNA content (Ionov et al.,  
1993; Lothe et al.,  1993; Thibodeau et al., 1998) and a poor mucinous differentiation 
(Lothe et al., 1993; Muta et al., 1996). 
To date, mutations in five human MMR genes have been described: hMSH2, hMLH1, 
hPMS1, hPMS2 and MSH6 (Wheeler and Bodmer, 2000). The majority of those with 
HNPCC have a germ line mutation in one theses genes with HNPCC have a germline 
mutation in one of these genes, with more than  90% of cases involving hMSH2 or 
hMLH1(Kinzler and Vogelstein, 1996). Furthermore, many HNPCC tumors harbor 
mutations in both alleles, one germline and one somatic, or total absence of wild type allele, 
indicating that both copies of an MMR gene are inactivated before a tumor develops 
(Papadopoulos et al., 1994; Leach et al., 1993).Somatic mutations of these genes are found 
less frequently in sporadic MSI cancers (Liu et al., 1995; Borresen et al., 1995), suggesting 
that novel genes may be involved. However, lack of hMLH1 or hMSH2 expression has been 
demonstrated in 95 per cent of sporadic MSI-H tumors (Thibodeau et al., 1998) and loss of 
  REVIEW OF LITERATURE 
24 
 
hMLH1 expression is known to be associated with hypermethylation of the promoter region 
of this gene. 
Of particular interest is the high frequency of TGF-β type II receptor (RII) mutations in 
MSI-positive colorectal tumors. The gene coding for this receptor contains mononucleotide 
repeats, analogous to microsatellites, and so is particularly sensitive to defects in DNA 
mismatch repair. Inactivating mutations of RII have been found in 90 per cent of colorectal 
cancers showing MSI, in most cases both alleles are affected (Parsons et al., 1995). RII 
mutations have also been studied in MSI-positive adenomas at various stages of progression 
(Grady et al., 1998 ).The earliest stage at which RII mutations were detectable was in high-
grade dysplastic adenomas, and in adenomas containing a focus of invasive carcinoma the 
prevalence of RII mutations was approximately 75per cent. These observations suggest that 
a mutation of TGF-βRII is a critical step in MMR-deficient colorectal tumor formation that 
RII behaves like a tumor suppressor and that its mutation correlates strongly with the 
progression of adenoma to carcinoma. However, it is interesting that RII mutations are also 
common in MSI-positive gastric cancer but rare in MSI-positive endometrial cancer 
(Myeroff et al., 1995).These findings suggest that RII mutations do not simply reflect MSI 
but are instead selected for and contribute to the genesis of gastrointestinal cancers. 
 
2.4.3 Transforming growth factor- β (TGF- β) pathway 
 
A more recently identified pathway in CRC carcinogenesis involves mutations along the 
TGF- β signaling cascade. TGF- β binds its cell surface receptor TGF- β RII with the 
subsequent activation of SMAD proteins. These proteins translocate to the nucleus and 
regulate genes involved in the inhibition of cellular proliferation (Takayama et al., 2006). 
Several mutations in TGF-bRII render this receptor resistant to the effects of TGF-β.  
Approximately 20% to 30% of CRCs display mutations in the TGF-b signaling pathway. In 
up to 90% of cases these mutations also display MSI (Kitisin and Mishra, 2006; Grady et 
al., 1999). Mutations also are identified in SMAD proteins that cause the TGF-b signaling 
pathway to become dysfunctional (Eppert et al., 1996; Ando et al., 2005). Direct 
interactions between SMAD proteins within the TGF-b pathway and signaling molecules in 
the Wnt pathway have been identified and it is suggested that these two pathways may work 
synergistically in promoting tumorogenesis (Labbe et al., 2000). The mutations involving 
the TGF-b pathway seem to be a late occurring event in the adenoma to carcinoma 
progression. 
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Figure .2:  Genes and Growth Factor Pathways That Drive the Progression of 
Colorectal Cancer. 
(Source: Molecular Basis of Colorectal Cancer. New England Journal of Medicine (2009). 
Vol. 25, pg. 361 
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2.5 DNA repair of alkylated bases 
 
Two main processes for the repair of alkylation damage to DNA have been described, one is 
a DNA glycosylase, which cleave the base-sugar bond of abnormal nucleotide residues and 
the other is a O
6
-alkylguanine transferase. Remarkable features are the relatively high 
degree of specificity of these DNA repair processes, and the similarity that has been 
observed in these major repair pathways between Escherichia coli and mammalian cells, 
including those of human origin,particularly on the O
6
-methylguanine-transferase (Lindahl, 
1982).  
The information on repair of O-alkylpyrimidines, although still rather limited, shows that: 
O
2
-methylcytidine and O
2
-methylthymine are repaired by the same enzyme (3-
methyladenine DNA glycosylase II), which repairs 3-methyladenine and 3-methylguanine; 
in Escherichia coli at least a 2-fold greater release from DNA is observed with the O
2
-
methylpyrimidines as compared with the N
3
-methylpurines (McCarthy et al., 1984); O
4
-
methylthymine is repaired by the methyltransferase that also acts on O
6
-methylguanine in 
DNA in E. coli (Laval  & Laval, 1984). In mammalian cells and in E. coli, O
6
-
methylguanine transferase can also function on ethylated, chloroethylated and propylated 
DNA, although with a lower rate of removal (Robins et al., 1983). 
 
 
2.6 O
6
-Methylguanine-DNA methyltransferase (MGMT) 
 
Studies in the 1970s and 1980s examined the formation and persistence of O
6
alkyl guanine 
in DNA originally in bacteria and rat liver and subsequently in other species. Studies on 
animals used carcinogenic dose regimes and in most cases, the formation, accumulation or 
persistence of this lesion in the DNA of specific tissues correlated with their susceptibility 
to carcinogenesis. This was attributed to the mutagenic properties of the base. The presence 
of O
6
-methylguanine was first reported in 1985 and this and other alkylation damage 
products are increasingly evident in human DNA although the sources of such damage have 
yet to be identified (Povey, 2000). 
The early studies showed that O
6
-methylguanine was lost from DNA in rodent tissues more 
rapidly than could be accounted for by cell turnover and this indicated the existence of an 
active repair system (Lawley and Orr, 1970; O‟Connor et al., 1973). The fact that this could 
be saturated and subsequently recover, following pre-treatment with various DNA 
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damaging agents was the first suggestion of the novel mechanism of this repair system 
(Kleihues and Margison, 1976).The characterisation of the repair processes responsible 
occurred more or less simultaneously in prokaryotic and eukaryotic systems. The 
prokaryotic proteins were initially shown to act on O
6
 MeG in methylated DNA and it was 
reasonable to refer to them as methyltransferases (hence MGMT). However, the term 
alkyltransferase is also frequently used and has the advantage that it avoids confusion with 
the DNA methyltransferase that generates 5-methylcytosine in DNA using S-
adenosylmethionine as a methyl group donor. More importantly, MGMT can act on the 
minor product O
4
methylthymine and clearly have a very broad specificity it is evident from 
work with alkylated DNA and low molecular weight pseudo-substrates that the human 
MGMT can act at different rates on a very wide range of O
6
 alkyl groups (Pegg, 2000). 
 
 
2.6.1 Occurrence and physiological effects of MGMT 
O6-Alkylguanine-DNA alkyltransferase was first isolated from E. coli in the late 1970s as 
the Ada protein, a dual function inducible repair protein, which regulates the adaptive 
response to low levels of alkylating agents (Demple et al., 1985; Foote et al., 1980; Lindahl 
et al., 1988; Olsson and Lindhal, 1980). E. coli has a second alkyltransferase, the 
constitutively expressed Ogt protein(Potter et al., 1987).The human MGMT cDNA was first 
isolated from a cDNA library by rescue of the ada phenotype in E. coli.(Tano et al., 
1990).The characterization of MGMT and its homologues is an ongoing process. O6-
Alkylguanine-DNA alkyltransferases are found in prokaryotes, archea bacteria and many 
eukaryotes, but not in the plant kingdom. The evolutionary conservation of MGMT suggests 
that it plays a fundamental role in maintaining genomic integrity. However, MGMT is not 
essential for cell viability. It has been shown for many cell types that sensitivity to 
alkylating agents inversely correlates with MGMT activity and that MGMT-deficient cells 
are more susceptible to spontaneous and alkylating-agent-induced toxicity and mutation. 
Furthermore, MGMT knockout mice are more susceptible to toxicity and tumor induction 
by alkylating agents, whereas mice over expressing MGMT are more resistant (Margison 
and Santibanez, 2002). Thus MGMT protects both normal cells and tumor cells against the 
toxic and mutagenic effects of O6-alkylating agents and is therefore a crucial factor in 
mediating the resistance to this class of chemotherapeutic agents. 
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2.6.2 MGMT Gene characterization and regulation 
The gene for AGT, which is referred to as MGMT, has been characterized from both human, 
where it is present on chromosome 10q26, and mouse, where it is present near the telomere 
of chromosome 7 (Iwakuma et al.,1996; Pieper et al.,1990; Tano et al., 1997). The 
organization of the gene is similar in both cases with five exons one non-coding and four 
introns, three of which are very large. The second intron in the mouse is >110 kb and three 
of the human introns each span >40 kb. Thus, MGMT is a very large gene (>170) kb. which 
encodes a mRNA of slightly less than 1 kb. A mouse 3T3 cell line selected for resistance to 
chloroethylating agents was found to have an amplification of the MGMT gene (Tano et al., 
1997). Such amplification appears to be a very rare phenomenon, which may be related to 
the size of the gene and to the means by which alkylating agents induce cell killing, being 
non-conducive to amplification mechanisms. 
The promoter region of the MGMT gene has been characterized as a 1.2-kb region located at 
positions -954 to + 203 in the gene. It is very CpG-rich, lacks TATA and CAAT boxes and 
has 10 Sp1 transcription factor binding sites. These features are all consistent with the 
constitutive expression of AGT in all tissues. The promoter contains two possible 
glucocorticoid response elements and two AP-1 sites located 1 kb upstream of the 
transcription start site. The GREs are not a perfect match with the consensus sequences but 
direct proof that AGT expression may be regulated by glucocorticoids has been provided 
both by showing an increased AGT activity in HeLa S3 cells treated with dexamethasone 
and by showing that this steroid increases expression of a luciferase reporter gene under the 
control of the MGMT promoter (Biswas et al., 1999). The changes were quite small with 
only a 2-fold increase in AGT activity and protein and a 3-fold increase in reporter gene 
expression. Nonetheless, there was a modest increase in resistance of the treated cells to 
BCNU. The possible importance of the AP-1 sites has been revealed by similar studies 
showing increased production of luciferase from the MGMT promoter-driven gene in cells 
transfected with c-jun and c-fos and that activators of protein kinase C such as TPA or DAG 
and inhibitors of protein phosphatases such as okadaic acid increase the level of AGT 
mRNA and increase resistance to BCNU in HeLa cells (Boldogh et al., 1998). As with 
dexamethasone, the level of increase was small, in the range of 4-fold. A 59-bp DNA 
sequence located at the first exon-intron boundary has been shown to act as an enhancer 
needed for efficient expression of the mRNA. A very interesting protein that binds to a 9-
mer sequence in this region has now been identified and was found to be in the nucleus of 
cells expressing AGT (Chen et al., 1997). In cells that exhibit the Mer- phenotype and lack  
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Figure 3: Structure of the human MGMT gene and factors known to affect the 
expression and activity of MGMT. The maximal promoter and exon 1 region is 
expanded to show more detail. The positions of exons 2-5 are shown as vertical bars. O 
indicates the origin of transcription. 
(Source: Variability and regulation of O6-alkylguanine±DNA alkyltransferase 
Carcinogenesis (2003) vol.24 pp.625-635  
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AGT expression, the enhancer binding protein was cytoplasmic. The factors responsible for 
the change in localization of this protein may therefore be of great importance in 
maintaining the level of AGT in mammalian cells. One possible way in which AGT levels 
might be regulated in response to DNA damage is through p53. p53 is known to interact 
with the transcription factor Sp1 and the MGMT promoter contains Sp1 sites. However, the 
findings are currently confusing and there may be both cellular and species variations in the 
effects as well as differential responses of basal and induced expression. Transfection of 
wild type but not mutant p53 blocked the MGMT promoter activity in Saos-2 cells and 
transduction with an adenoviral vector expressing p53 down regulated the AGT content of 
human fibroblasts (Harris et al., 1996). Down regulation of the human MGMT promoter by 
p53 was also seen in rodent cell lines (Grombacher et al., 1998). However, ionizing 
radiation is known to induce AGT and p53 (Rafferty et al., 1996) suggesting that any 
increase in p53 should be associated with a rise in AGT content. This would also make 
sense in terms of the generally accepted role of p53 in enhancing DNA repair. In support of 
this concept, it has been reported that ionizing radiation fails to induce AGT in p53 null 
mice and the response is ablated in mice with only one copy of the p53 gene (Rafferty et al., 
1996). Also, the expression of reporter genes under the control of the MGMT promoter is 
increased by ionizing radiation in rodent cells with wild type p53 but not with mutant p53, 
and only the cells with wild type p53 showed a radiation-induced increase in AGT activity 
(Grombacher et al., 1998).  
Although the basal level of AGT in the mouse tissues studied was unaffected by p53 status 
(Rafferty et al., 1996), the level of AGT in astrocytes was much reduced in mice lacking 
p53 (Nutt, et al., 1999). It is clear that much more work needs to be carried out on the role 
of p53 in regulating AGT levels in both the basal and induced states. Experimental 
protocols in which un-physiologically high (or low) levels of p53 are used may not provide 
relevant information and the extrapolation of results obtained with mice to human cells may 
not be straightforward. More careful examination of the interaction of p53 with components 
of the AGT transcription system is needed. In this regard, it should be noted that the 
inhibitory effect of p53 on basal AGT expression may not require the p53 DNA binding 
domain (Grombacher et al., 1998).  
 
2.6.3 Structure of MGMT Protein 
Despite the extremely low primary sequence identity between human, E. coli, and the 
archae bacteria Pyrococcus kodakaraensis (Pk). AGT (14% identity, 26% similarity.), the 
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overall domain structure and fold are nearly identical between the three homologs (Moore et 
al., 1994; Hashimoto et al., 1999; Daniels et al., 2000;   Wibley et al., 2000). AGT exhibits 
a two-domain α/β fold with overall dimensions of approximately 20×35×40 A°. While the 
three species have no significant primary homology in the N-terminal domain 
(approximately residues 1–85), they exhibit a conserved a/β roll. All three structures have a 
three-stranded anti-parallel β-sheet followed by two (human, bacterial.) or three (Pk) 
helices, with relatively small differences in the lengths and orientation of these secondary 
structures. 
The topology of the C-terminal domain is absolutely conserved, being composed of a short 
two stranded parallel β-sheet, four a-helices, and a 310 helix bearing the invariant active-site 
PCHR motif. The nucleophilic cysteine lies near the bottom of a solvent accessible groove 
roughly 7 A° wide, 9 A° deep and 14 A° long that defines an O6-alkylguanine binding 
channel. Immediately preceding the active-site motif are two overlapping, tight turns 
stabilized by an absolutely conserved asparagine (the Asn-hinge), and a helix-turn-helix 
(HTH) DNA-binding motif (Fig 2.5) 
While the overall structures of AGT from the three kingdoms of life are remarkably 
conserved, some differences do exist. Human AGT contains a zinc-binding site that does 
not exist in the bacterial or hyperthermophilic structures. The Zn (II) Ion bridges three 
strands of the N-terminal b-sheet and the coil immediately preceding the domain-spanning 
helix via tetrahedral ligands (Cys5, Cys24, His29, and His85 (Daniels et al., 2000). These 
ligands are absolutely conserved in the known mammalian sequences, implying that this 
binding site may be general to higher eukaryotes. The role of the zinc ion is likely structural, 
serving to stabilize the interface between the N- and C-terminal domains by tethering the 
domain-spanning helix to the three strands of the N-terminal β-sheet. Consequently, the His-
tagged human structure (Wibley et al., 2000), which lacks this Zn(II) ion, shows small 
conformational differences and increased disorder in the N-terminal domain (Daniels et al., 
2000). This slight structural relaxation is presumably due to the removal of Zn during 
purification over metal affinity columns. Loss of zinc stabilization may also account for 
approximately two-fold reduction in the apparent second-order rate constants observed for 
His-tagged relative to native recombinant AGT (Daniels et al., 2000; Goodtzova et al., 
1998). 
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Figure 4: Human MGMT X-ray crystallographic structure, zinc site, and DNA 
binding. (A) Unreacted MGMT structure (pdb 1eh6). The N-terminal domain is shown 
in green, the C-terminal domain is shown in yellow, and the HTH motif is shown in 
blue. The active site cysteine, arginine finger, “Asn hinge”, and zinc ligands are shown 
in ball-and-stick representation. (B) DNA-bound MGMT structure (pdb 1t39). MGMT 
uses the recognition helix of the HTH motif to bind the minor groove of DNA. 
 [Source: Tubbs, J.L., Pegg, A.E., Tainer, J.A. (2007). DNA binding, nucleotide flipping, 
and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and 
its implications for cancer chemotherapy DNA Repair; 6(8): 1100–1115]. 
 
 
 
 
 
 
 
 
 
 
  REVIEW OF LITERATURE 
33 
 
2.6.4 Mechanism of MGMT action 
The biochemistry of the repair reaction and the amino acid residues required have been 
extensively explored by site- directed mutagenesis (Crone et al., 1994),  selection of cDNAs 
from random libraries (Encell et al., 1998) and the reaction with alkylated oligonucleotides 
and structurally diverse pseudo-substrates (Spratt et al., 1999). The current model for the 
mechanism of MGMT is that it binds to DNA via a helix-turn-helix motif in the C-terminal 
domain. The second helix contains an arginine ``finger'' that flips out the alkylated base into 
the active site. A histidine residue within the highly conserved active site motif PCHRV/I 
and a glutamic acid residue form a hydrogen bond network with the active site cysteine 
residue affecting the transfer of the alkyl group to the latter. This stoichiometric reaction 
results in ``suicidal'' inactivation of MGMT and alters the conformation of its DNA-binding 
domain. The alkylated protein thus becomes detached from DNA and also targeted for 
degradation by ubiquitination (Srivenugopal et al., 1996). The auto-inactivating mechanism 
means that the continued repair of O 
6
-alkylation damage in DNA requires de novo 
synthesis of active protein. The active site pocket must be quite flexible since a wide range 
of different structures are recognised as substrates, in accord with the concept of ``induced 
fit''. MGMTs from different sources can act at different rates on the same pseudo-substrate, 
however, so that primary structural differences are also important. Modification of the 
amino acid sequence has been used to change substrate specificity (Encell et al., 1998) in 
the development of protective gene therapy strategies. 
 MGMTs have no known cofactor requirements. Although evidence has been presented for 
the co-localisation of MGMT with nascent RNA (Ali et al., 1998), the rate of removal of 
O
6
MeG from transcribed and non-transcribed genes is similar (Engelbergs et al., 1998). 
Phosphorylation of the protein, resulting in a decrease in activity, has recently been reported 
(Srivenugopal et al., 2000). 
One exception to the general alkyl transfer repair mechanism is the action of the protein on 
N1-O
6
-ethenoguanine. This is formed after chloroethylation of the O
6
-position of guanine 
and is an intermediate in DNA inter strand crosslink formation. Whilst the chloroethyl 
group can be removed by the alkyl transfer mechanism, in the case of N1-O
6
-ethenoguanine, 
MGMT forms a covalent bond with the C atom next to the O 
6
 atom; but as the etheno 
group is attached to the N1 atom, the DNA becomes covalently attached to the protein 
(Gonzaga et al., 1992). Whether or not this reaction occurs in vivo and, if so, the fate of the 
bound MGMT molecules and the biological significance of this, if any, remain to be 
established. There is some evidence that nucleotide excision repair may be involved in the  
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Figure 5: The AGT active site and proposed reaction mechanism. (A) Hydrogen bond 
network andproposed reaction mechanism for AGT. To facilitate attack at the O6-
alkyl carbon, His146 actsas a water-mediated general base to deprotonate Cys145. The 
resultant imidazolium ion isstabilized by Glu172. Tyr114 donates a proton to N3 of 
O6-methylguanine. (B) Stereo viewof the X-ray crystallographic structure of the AGT 
C145S-DNA complex (pdb 1t38) showingthe active site, O6-methylguanine substrate, 
and hydrogen bond network. 
[Source: Tubbs, J.L., Pegg, A.E., Tainer, J.A. (2007). DNA binding, nucleotide flipping, 
and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and 
its implications for cancer chemotherapy DNA Repair; 6(8): 1100–1115]. 
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processing of such a lesion given that NER-defective cells are more susceptible to 
chloroethylating agent toxicity (Wu et al., 1992). 
Transfer of alkyl groups from the O
4
-position of thymine in DNA by mammalian MGMT is 
inefficient and there is evidence that binding to such lesions can result in shielding of this 
from repair by the nucleotide excision repair pathway (Samson et al., 1997). More recently, 
MGMT has been shown to protect cells against the toxic effects of cyclophosphamide, 
possibly via the repair of acrolein adducts in DNA (Friedman et al., 1999). 
 
2.6.5 MGMT hypermethylation and protein expression 
Due to the important role of MGMT in DNA repair, several studies have been undertaken to 
find correlations between MGMT methylation status, expression, and tumorigenesis. 
 
2.6.5.1 MGMT in non-tumorous tissues.  
As a repair enzyme, MGMT is expressed in every human tissue, but its level in individual 
tissues varies, even in subpopulations. The levels and activity of MGMT in healthy cells are 
regulated by its protein phosphorylation status (Srivenugopal et al., 2000), the binding of 
the E6 papilloma virus oncoprotein (Srivenugopal  and Ali-Osman, 2002) and the action of 
p53 (Harris et al., 1996), glucocorticoid hormone (Biswas et al., 1999) and other 
transcription factors over its 50-CpG island, which includes a classical promoter without 
TATA and CAAT boxes and a 59 bp enhancer element located at the first exon–intron 
boundary (Harris et al,.1991). Its expression is highest in the liver, relatively high in lung, 
kidney and colon, and the lowest in pancreas, hematopoietic cells, lymphoid tissues and 
brain (Gerson, 2004; Sabharwal and Middleton, 2006; Kaina et al., 2007; Liu and Gerson 
2006; Soejima et al., 2005; Pegg et al., 2007; Helleday et al., 2008; Pieper, 1997). 
Furthermore, MGMT expression levels in tissues remain stable with age (Bobola et al., 
2007). The study of Bobola examined MGMT activity in 71 brains at 6 to 19 weeks of 
gestation and found activity in such developing brains to be directly correlated with 
gestational age and that the proportion of specimens negative for MGMT at 19 weeks was 
approximately that observed in adults. Prior to 19 weeks of age, fetal brain levels of MGMT 
were low, suggesting that exposure to exogenous and endogenous alkylators prior to that 
time may, due to vascular permeability, such as the blood-brain barrier, result in increased 
susceptibility to tumor formation in later life (Bobola et al.,2007). 
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2.6.5.2 MGMT in tumor tissues  
Several studies have found that MGMT protein is decreased in some tumors with respect to 
their normal tissue counterpart (Gerson et al., 1986; Citron et al., 1992) .In fact a  subset of 
tumor cell lines, termed Mer-, completely lack MGMT activity (Day et al., 1980). For 
example, Silber assessed levels of MGMT in normal brain tissue and in primary brain 
tumors (Silber et al., 1998). They found relatively but significantly lower amounts of 
MGMT in tumors (Bobola et al. 1996). Also of interest were the observations of Sawhney 
et al. who found significant loss of MGMT expression in the transition of hyperplasia to 
dysplasia in patients with oral squamous cell carcinoma (Sawhney et al., 2007). This 
suggested that diminution in MGMT expression is an early step in oral tumorigenesis. As 
loss of expression is not commonly due to deletion, mutation or rearrangement of the 
MGMT gene (Day et al., 1980; Fornace et al., 1990; Pieper et al., 1990) or mRNA 
instability (Kroes and Errickson, 1995), other causes for loss of activity are expected. 
Methylation of cytosine in CpG dinucleotides is the main epigenetic modification of DNA 
in normal mammalian cells (Esteller and Herman, 2002). The human MGMT gene 
possesses a CpG island in the 5‟ portion of the gene (Harris et al., 1991). The region from 
−249 to +259 at the transcription start site is critical in DNA methylation-associated 
silencing (Qian and Brent, 1997). Hypermethylation of normally unmethylated  CpG islands 
in the promoter regions of many genes, including p16INK4a, p14ARF, VHL, BRCA1, 
hMLH1 and E-cadherin, correlates with its loss of transcription (Esteller et al., 2001a,      
Esteller, 2002b). Hypermethylation of the MGMT CpG Island as the cause of MGMT 
transcriptional silencing in cell lines defective in O6-methylguanine repair has been 
demonstrated (Costello et al., 1996; Qian and Brent., 1997; Watts et al., 1997; Danam et al., 
1999; Esteller et al., 1999a). As for other genes inactivated by CpG island methylation, 
hypermethylation of the promoter region is accompanied by histone hypoacetylation and 
methylation (Kondo et al., 2003), binding of specific methyl-binding proteins (Fraga and 
Esteller, 2002) and loss of nucleosome positioning (Patel et al., 1997), all of these 
alterations rendering a „closed‟ chromatin state that prevents gene transcription (Ballestar 
and Esteller, 2002). As additional proof of causality, in vitro treatment of cancer cells with 
demethylating drugs restores MGMT expression (Qian and Brent, 1997; Esteller et al., 2000 
a). To study the relevance of the promoter hypermethylation of the MGMT gene in vivo in 
cancer patients, Estellar examined a large series of more than 500 primary human tumors 
and corresponding normal tissues for MGMT aberrant methylation using methylation-
specific PCR and its relation with MGMT expression (Esteller et al., 1999 a). MGMT 
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function is lost frequently in association with hypermethylation of the promoter region in a 
wide spectrum of human tumors (Esteller et al., 1999 a). Their initial findings demonstrated 
a specific profile of MGMT hypermethylation in human cancer that indicated gliomas, 
lymphomas, colon, head and neck and non-small-cell lung carcinomas as the main tumor 
targets for the epigenetic inactivation of MGMT (Esteller et al., 1999a). This profile, has 
been expanded in additional reports of MGMT inactivation in other tumor types (Toyooka 
et al., 2001; Virmani et al., 2001; Choy et al., 2002; Lee et al., 2002; Smith-Sorensen et al., 
2002). This aberrant MGMT methylationhas been correlated with the loss of MGMT 
protein (Esteller et al., 1999 a; Esteller and Hermann, 2002; Herfarth et al., 1999.), lack of 
mRNA expression (Esteller et al., 2000 a; Yin et al., 2003) and loss of enzymatic activity 
(Herfarth et al., 1999).  
The constellation of tumor types where MGMT hypermethylation can be invoked has also 
been further understood with its analysis in a comprehensive panel of 70 human cancer cell 
lines (Paz et al., 2003). Furthermore, the CpG island hypermethylation-associated silencing 
of MGMT occurs very early in human tumorigenesis, such as in small colon adenomas 
(Esteller and Hermann, 2000), strongly supporting its relevant role in carcinogenesis. 
MGMT promoter hypermethylation has also been demonstrated in the serum DNA of lung 
cancer patients (Esteller et al., 1999 b), and head and neck cancer patients (Sanchez-
Cespedes et al., 2000) as well as other biological fluids, including sputum (Palmisano et al., 
2000) and saliva (Rosas et al., 2001). Capper evaluated MGMT expression as a prognostic 
factor in diffuse astrocytic tumors (n=162) ranging from low to high grade. The study found 
MGMT expression to be less prominent as the tumors became more malignant (Capper et 
al., 2008). In other words, high-grade gliomas showed less MGMT expression than low-
grade gliomas, suggesting a loss of MGMT expression in the process of anaplastic 
transformation (Capper et al., 2008). Thus, it may be possible to use MGMT expression as a 
prognostic indicator, MGMT levels being a reflection of tumor grade. In colorectal cancer, 
Zhang reported longer survival rates in patients with MGMT negative surgical margins; 
however methylation did not have a significant effect upon overall survival in the 24-case 
series of colorectal cancer (Zhang et al., 2007). Thus, it appears that methylation of the 
MGMT promoter region is an important predictor of patient survival in various tumor types. 
 
2.6.6 MGMT and protection against point mutations 
The transcriptional silencing of MGMT by promoter hypermethylation instigates an 
important mutator pathway in human cancer, because the O6-methylguanine adducts, 
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resulting from alkylating agents are not removed, thereby producing G:C to A:T 
transitions(Fig.2.7). Supporting these data, the most common mutations caused by 
alkylating agents are G:C to A: T transitions (Horsfall et al.,1990), exemplified in the 
frequent generation of G to A transitions in the oncogene K-ras when the carcinogen N-
methylnitrosourea (that forms O6-methylguanine adducts) is used in experimentally induced 
tumor systems (Sukumar et al., 1983; Mitra et al., 1989). Avoidance of the mutagenic effect 
is directly related to the presence of a functional MGMT protein (Pegg et al., 1995). In vitro 
assays show that endogenous MGMT expression protects mammalian cell lines from 
spontaneous G:C to A: T transitions in the aprt gene(Aquilina et al., 1992). Animal models 
also show that transgenic mice over expressing MGMT are protected against O6-
methylguanine-DNA adducts caused by methyl-nitrosourea (Dumenco et al., 1993) and 
against G to A mutations in K-ras in aberrant colorectal crypt fociand lung tumors (Zaidi et 
al., 1995; Liu et al., 1999).This link between MGMT inactivation and K-ras transition 
mutations in human tumors was first observed in 2000 (Esteller et al., 2000 ).The incidence 
of K-ras activation varies widely among carcinomas. K-ras mutation is rare in human 
primary breast carcinomas, but occurs in approximately half of colorectal carcinomas. This 
mutation distribution strongly resembles the pattern of MGMT promoter hypermethylation 
described (Esteller et al., 1999 a), while MGMT aberrant methylation is not present in 
breast carcinomas where K-ras mutations are extremely rare, it occurs in approximately 
40% of cases of colorectal carcinomas associated with loss of MGMT expression, and is 
also frequent in non-small-cell lung carcinoma (Esteller et al., 1999b) where K-ras 
mutations are frequent. MGMT promoter hypermethylation was an early event in human 
colorectal tumorigenesis linked to the appearance of G to A mutations in the K-ras 
oncogene (Esteller et al., 2000).The association between MGMT methylation and K-ras 
mutations has now been reported not only in colon cancer in (Whitehall, 2001) but also in 
gastric and gall bladder cancers (Park et al., 2001; Kohya et al.,2003).The tumor suppressor 
p53 is the most commonly mutated gene in human cancer, and transition mutations 
constitute the most common p53 mutations (Greenblatt et al., 1994; Pfeifer, 2000). 
Approximately 52% of the mutational events are mis-sense transitional changes, and, of this 
subset, 72% are G:C to A: T transitions (Greenblatt et al., 1994). The profile of the 
mutational spectrum varies according to tumor type. Lung and head and neck tumors of 
smokers have a higher number of transversions, whereas colorectal tumors have the highest 
rate of transition mutations, reaching 70% of the total number of p53 mutations (Greenblatt 
et al., 1994). These last mutations occur frequently in CpG dinucleotides, which are 
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normally methylated (Pfeifer, 2000; Rideout et al., 1990; Tornaletti and Pfeifer, 1995), 
through increased rates of spontaneous deamination at methylcytosine, although other 
mechanisms are also conceivable. However, 17% of p53 mutations are transition mutations 
in non-CpG dinucleotides, where this causality cannot be invoked (Greenblatt et al., 1994). 
Thus, G:C to A: T changes in p53 in non-CpG and CpG dinucleotides could be attributable, 
in part, to a defect in MGMT that allows the persistence of O6-methylguanine and its 
reading as an adenine (Fig 2.7).Promoter hypermethylation of MGMT was strongly linked 
to the presence of G:C to A: T transition mutations in p53, particularly in non-CpG 
dinucleotides (Esteller et al., 2001) in colon cancer and has also been found in glioma 
(Nakamura et al., 2001; Yin et al., 2003), liver (Zhang et al., 2003) and non-small-cell lung 
carcinomas (Wolf et al., 2001). Yet to be classified is the particular source of promutagenic 
adducts in the O6 position of guanine not repaired by MGMT in each tumor type. For 
colorectal tumors, the alkylating agents causing the pro-mutagenic lesion may be provided 
from dietary nitrates reduced in the proximal colon by bacteria, by nitrosation of amines and 
amides derived from protein catabolism (Ward et al., 1989; Bartsch et al., 1990; Rowland et 
al., 1991). For other cancers, these carcinogens are ever more speculative. Not all adducts 
are repaired with the same efficacy. O6-ethylguanine is removed faster than the O6-
methylguanine, perhaps preventing ras mutations in certain tumor types more exposed to 
these xenobiotics (Engelberg et al., 1998). Among the glial tumors, MGMT epigenetic 
inactivation (Esteller et al., 1999a) and MGMT loss or reduced activity (Hongeng et al., 
1997; Silber et al., 1998) are common features, and these epigenetic events associate with 
the presence of transition mutation in p53 (Nakamura et al., 2001; Yin et al., 2003). Yet, 
carcinogens exposure is not frequently associated with the development of brain tumors. 
 
2.6.7 MGMT and protection against carcinogenesis 
 
The first report to conclusively show that DNA repair by AGT prevents cancer used the 
MNU-induced thymic lymphoma mouse model. Human MGMT thymic over expression in 
these mice completely suppressed the development of lymphoma (Dumenco et al., 1993) 
under conditions in which the O6-MG adducts were efficiently removed (Liu et al., 1994). 
Other transgenic mouse models with tissue-targeted MGMT expression had a reduction in 
liver tumours after treatment with dimethyl nitrosamine (Nakatsuru et al.,1993),two-stage 
skin tumours induced by MNNG  (Kaina, 2004 )and lung tumours induced by NNK (Liu et 
al., 1999 ).When MGMT was over expressed in C3H mice, which normally  
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Figure 6: The promoter hypermethylation of MGMT in a wide spectrum of human 
tumours uncovers a new mutator pathway, because the O6-methylguanine adducts 
resulting from alkylating agents are not removed and this consequently causes G:C to 
A:T transitions that affect genes required for genomic stability. 
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have a high frequency of spontaneous liver tumours ,liver tumour formation was reduced, 
indicating that endogenous O6-MG lesions might be responsible for these tumours in 
susceptible mice (Zhou et al.,2001).Furthermore, in mice with other DNA-repair defects, 
such as MMR deficiency, transgenic MGMT over expression protected from MNU-induced 
carcinogenesis as well (Qin et al., 1999).Mice predisposed to develop lymphomas because 
of over expression of the LIM domain oncogene-1 (LMO1)( Qin et al., 1997) or loss of p53 
are also protected from methylating-agent-induced lymphomagenesis by MGMT over 
expression (Reese et al., 2001). As expected, Mgmt-knockout mice (Mgmt–) are more 
sensitive to methylating and chloroethylating agents than wild-type mice (Mgmt+).        
Although Mgmt-knockout mice are killed by low doses of MNU and BCNU (Glassner et al., 
1999), they can be protected by transplantation of normal marrow cells. In competitive 
repopulation assays, mixing wild-type with Mgmt-knockout marrow cells followed by 
transplantation and treatment with MNU results in a strong survival advantage in favor of 
the wild-type cells( Reese et al., 2001). Furthermore, these mice survive doses of MNU that 
kill the knockout mice. This indicates that in the absence of Mgmt, marrow sensitivity, 
rather than other organ toxicity is dose limiting for chemotherapeutic alkylating agents 
(Reese et al., 2001). Perhaps surprisingly, double knockouts of Mgmt and the MMR protein 
Mlh1 are highly sensitive to mutagenesis, but are resistant to drug-induced cell death 
(Kawate et al., 1998).This is because without MMR proteins there is no recognition of 
persistent O6-MG DNA adducts. 
 
 
2.6.8 MGMT Polymorphisms 
 
There is an increasing realization that polymorphisms in genes involved in either the 
metabolism of carcinogens/toxins or the responses to damage caused by these agents 
including DNA repair may have a profound effect on sensitivity to these agents and thus on 
human health. Identification of polymorphic variants in such genes and understanding the 
mechanistic implications of such alterations is now a major research area. A large number of 
polymorphisms in the MGMT locus have been described. These slightly altered forms of 
MGMT may be useful as diagnostic tools, pre-treatment factors and indicators of risk of 
having a tumor. Some of the forms act as pre-treatment assessment tools as they are less 
sensitive to the action of certain MGMT inhibitors (Pegg et al., 2007; Bugni et al., 2007). In 
addition, they do have risk associations in the setting of breast, lung, head and neck, 
  REVIEW OF LITERATURE 
42 
 
colorectal and other types of cancer (Pegg et al., 2007; Bugni et al., 2007; Ogino et al., 
2007; Povey et al., 2007). To date, 438 polymorphisms have been found (Povey et al., 
2007). They showed minor allele frequencies, defined as the relative abundance of a 
particular allele type among all individuals of a population, usually over 0.05% , and most 
affecting 5‟-UTR,  3‟-UTR  and introns  (Pegg et al., 2007; Bugni  et al .,2007; Povey et al., 
2007). The most common variants of MGMT are Ile143Val and Lys178Arg. Existing in 
nearly perfect disequilibrium with one another, they comprise 20% of observed variations 
(Bugni et al., 2007). Other known variations affecting the primary structure of MGMT 
include Trp65Cys, Leu84Phe,Gly160Arg, Gly135Thr, Gly290Ala, Cys485Ala, Cys575Ala, 
Gly666Ala, Cys777Ala, Gly795Cys, Ala1034Gly and Cys1099Thr (Pegg et al. 2007). Both 
Leu84Phe and Ile143Val are of interest as they are situated close to the Cys145 active site 
and may affect MGMT function (Pegg et al., 2007; Bugni et al., 2007). . Most studies have 
focused on three common coding sequence polymorphisms - Leu84Phe (SNP ID: rs12917) , 
Ile143Val (rs2308321) and Lys178Arg (rs2308327) . 
 
2.6.8.1 Ile143Val 
Ile143Val, a polymorphism found in 18% of individuals of European origin, is not present 
in Nigerian and Japanese descendants (Povey et al., 2007). The allele frequency is 
approximately 0.15% in Caucasians and is only rarely found in Asians and Africans (Bugni 
et al., 2007). Located in a region of high linkage disequilibrium with 19 other 
polymorphisms, it has no effect upon pancreatic, prostate, oral and gastric cancer nor on 
melanoma risk, but is associated with a reduced risk in women for colorectal as well as head 
and neck cancer (Pegg et al., 2007; Bugni et al., 2007). Its correlation with lung, breast and 
endometrial cancer is debated (Pegg et al.; 2007; Bugni et al., 2007). Some studies suggest 
it has no effect upon lung cancer (Krzesniak et al., 2004; Yang et al., 2004; Huang et al; 
2005), whereas another found it to be weakly associated with an increased risk (Cohet et al., 
2004). Yet a third study reported a two-fold increased risk of lung cancer, particularly 
adenocarcinoma, in Caucasians and African-Americans with the Ile143Val (Kaur et al., 
2000). Similarly, one study noted that this variation had no effect upon breast cancer (Han 
et al. 2006), while another suggested that fruit and vegetable consumption resulted in a 
reduced breast cancer risk in women (Shen et al., 2005). A recent study suggested that there 
is a reduced risk of endometrial cancer in smokers with the Ile143Val polymorphism. 
Interestingly, the same study found that Ile143Val carriers who had been smoking more 
than 30 pack-years had a significantly lower risk for endometrial cancer as compared to 
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non-smoking women homozygous for Ile143Val (Han et al., 2006). The Ile143Val 
polymorphism results in MGMT equally capable of repair as is wild-type MGMT (Bugni et 
al., 2007). In fact, after being incubated with O6-(4-bromothenyl) guanine (Patrin- 2, an 
MGMT inhibitor), it has been shown to be 1.3 times more active in repairing O6-MG 
adducts than is the wild type (Bugni et al., 2007). It is also able to repair O6-[4-oxo-4-(3-
pyridyl) butyl] guanine (O6-pobG) more effectively than both the wild-type and the 
Leu84Phe polymorphic MGMT (Pegg et al., 2007). Ile143Val MGMT is less sensitive to 
O4-benzylfolate (BF), a powerfulMGMT inhibitor and slightly less sensitive to Patrin-2, the 
MGMT inhibitor mentioned above (Pegg et al., 2007). The Ile143Val variant has reduced 
activity towards low molecular weight inhibitors, such as O6-BG and Patrin-2 (Pegg et al., 
2007). Ile143Val tumors respond poorly to chemotherapy (Bugni et al., 2007). The role of 
Ile143Val expression is of importance as a pre-treatment marker since patients with this 
phenotype express reduced sensitivity to MGMT inhibitors, a factor that may affect 
treatment. 
 
2.6.8.2 Lys178Arg 
This polymorphism has no effect upon the risk of developing breast, pancreatic, prostate 
and gastric carcinoma or melanoma (Pegg et al., 2007; Krzesniak et al., 2004;  Huang et al., 
2005; Han et al., 2006; Shen et al., 2005; Ma et al.,2003; Ritchey et al.,2005; Jiao et al. 
2006). Some studies showed a weak association between Lys178Arg and increased lung 
cancer risk (Pegg et al., 2007; Cohet et al., 2004;  Kaur  et al., 2000), whereas another study 
showed it to be associated with a lower lung cancer risk (Povey et al., 2007). Lys178Arg is 
associated with reduced risk of colorectal, as well as head and neck cancer in women, and 
endometrial cancer in heavy smokers (Pegg et al., 2007; Bugni et al., 2007; Huang et al., 
2005). This polymorphism repairs O6-[4-oxo-4-(3 pyridyl) butyl] guanine (O6-pobG) more 
effectively than does either the wild-type or the Leu84Phe polymorphism MGMT (Pegg et 
al., 2007). The Lys178Arg variant is less sensitive to the inhibitor BF and slightly less 
sensitive to Patrin-2 (Pegg et al., 2007). Thus, Lys178Arg is also linked to an overall poorer 
response to chemotherapy (Pegg et al. 2007). As it is genetically related to the Ile143Val 
variant (Pegg et al., 2007; Bugni et al., 2007), there are studies on the association of the two 
forms. One found that the Ile143Val and Lys178Arg polymorphism carriers are better 
protected against the mutagenic effects of alkylating agents in comparison to wild-type 
carriers (Pegg et al., 2007). As a prognostic factor, Lys178Arg expression appears to be 
useful in differentiating between patients in whom chemotherapy and MGMT inhibitor 
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therapy would or may not be successful, since this polymorphism is less sensitive to MGMT 
inhibitors and is associated with a poorer chemotherapeutic response. 
 
2.6.8.3 Leu84Phe 
The Leu84Phe variation has an allele frequency of 0.15% (Bugni et al., 2007). Its 
expression does not vary significantly by race, but it is somewhat more prevalent among 
Caucasians than Chinese (Pegg et al., 2007). One study demonstrated a correlation between 
this polymorphism and cancer risk, alcohol intake, body mass index (BMI) and post-
menopausal hormone (PMH) use (Tranah et al., 2006).This polymorphism has no effect 
upon lung, oral and gastric cancer or melanoma risk (Krzesniak et al., 2004). It is, however, 
associated withan increased risk of breast cancer in heavy smokers (Shen et al., 2005), an 
increased incidence of glioblastoma multiforme (Inoue et al., 2003) as well as an increased 
risk of prostate (Ritchey et al., 2005) and bladder carcinoma (Li et al., 2005). Leu84Phe 
polymorphism carriers have a lower risk of endometrial cancer (Han et al., 2006), a lower 
incidence of head and neck cancer (Huang  et al., 2005) and colorectal cancer associated 
with a better prognosis (Pegg  et al., 2007; Moreno et al., 2006). Furthermore, women who 
consumed more than 0.5 alcoholic beverages per day with the Leu84Phe polymorphism had 
an increased risk of colorectal cancer, while those with the allele who drank less had a lower 
risk (Tranah et al., 2006). In addition, women with the polymorphism and a body mass 
index (BMI) ≥25 had a lower risk of colorectal cancer than women with a BMI <25 who 
were homozygous for the wild-type allele (Tranah et al., 2006). In those homozygous for 
the wild-type allele, PMH use was inversely proportional to colorectal cancer risk (Tranah 
et al., 2006). Interestingly, no such correlation was noted in carriers of the Leu84Phe 
polymorphism. The same study found no association between colorectal cancer, 
polymorphism, BMI, and environmental factors including smoking and alcohol intake 
(Tranah et al., 2006). Leu84Phe is as capable as wild-type MGMT in the repair of O6-MG 
adducts (Pegg et al., 2007). One study found Leu84Phe variant proteins to be more 
susceptible to NNK-induced aberrations than the wild type (Bugni et al., 2007). It was also 
suggested that the Leu84Phe polymorphism may affect Zn2+ binding to MGMT, which is 
known to enhance MGMT activity (Bugni et al., 2007). Although the function of this 
polymorphism is very similar to that of the wild type, its expression may be of prognostic 
utility in heavy smokers, since NNK is primarily found in tobacco smoke (Pegg et al., 2007; 
Bugni et al., 2007). 
 
  REVIEW OF LITERATURE 
45 
 
2.6.9 Therapeutic manipulation of MGMT gene 
 
Given its presence in human DNA and its mutagenic, toxic and recombinogenic potential, it 
seems unavoidable to conclude that O6-alk G can potentially be responsible for human 
cancer. However, whilst environmental alkylating agents have been extensively studied, the 
contribution of such exposures to cancer in the general population is not known. An 
understanding of the mechanisms of endogenous formation of this lesion and indeed of any 
exogenous agents that might enhance endogenous formation will help to define the relative 
contributions of exogenous and endogenous damage. This may lead to the identification of 
strategies that will reduce the levels of O6-alk G or its biological impact. It is also possible 
that further exploration of the factors affecting ATase expression might eventually allow 
modulation of ATase levels by means of exogenous agents, perhaps even in a tissue-specific 
manner. However, this does not appear to be a practical proposition at the present time. In 
terms of cancer therapy, agents that decrease ATase activity in tumours can make them 
more sensitive to the toxic effects of O6-alkylating agents, at least in experimental models. 
This is a strategy that is currently being pursued in cancer patients (Gerson, 2002): low 
molecular weight pseudosubstrates (O
6
-BG, O
6
-BTG) of ATase are in clinical trial (Spiro et 
al., 1999; Schilsky et al., 2000; Friedman et al., 1998 ), and other approaches, including 
antisense and genetic suppressor elements are being explored in model systems. However, 
unless these strategies can be directed towards tumour cells, normal tissues are also likely to 
be sensitized to the toxic side effects of such therapies. Indeed this is the case in the trials 
thus far reported: it has been necessary to reduce the dose of the alkylating agents because 
of increased myelo-suppression (Roth et al., 2000). Normal cell specific up-regulation may 
be an approach to circumvent this, but as already stated, it is not yet known how to effect 
this using exogenous agents. However, in the case of myelo-suppression, ex vivo 
haemopoietic stem cell transduction with retrovirus harboring ATase is being actively 
pursued (Roth et al., 2000; Jelinek et al., 1999). This approach could be used in the absence 
of repair inhibitors as it would be expected to protect against bone marrow toxicity and even 
allow O6-alkylating agent dose escalation. Nevertheless, current strategies are exploiting 
mutant versions of ATase that are resistant to inactivation by pseudo-substrates (Pegg et al., 
2000; Encell et al., 1998) so that tumour sensitization and normal tissue protection can be 
achieved simultaneously by the use of inactivating agents. 
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The study was a case control undertaken to understand the etiology of colorectal cancer 
in Kashmir. Subjects with histopathologically confirmed colorectal carcinoma were 
evaluated. The colorectal carcinoma samples were collected from the Department of 
Surgery, Government S.M.H.S Hospital, Srinagar either by means of surgical resection 
or endoscopically. Histopathologically confirmed normal were taken as controls. The 
study included 70 surgically obtained colorectal samples among which 50 were obtained 
from colorectal cancer patients and 20 were histopathologically normal colorectal 
samples. All the samples were histopathologically confirmed before further processing. 
All ethical considerations were taken care of during the study and the recruitment 
process was started only after ethical clearance from the Departmental Ethical 
Committee as per norms was obtained. Record was maintained of the complete case 
history of the patients. The various methods that were used to analyse the epigenetic 
silencing of DNA repair gene MGMT by its promoter hypermethylation at CpG islands 
as a part of this study are described under.  
Analytical reagents like absolute alcohol (ethanol), agarose, ethidium bromide, EDTA, 
TRIS acid and base, sucrose etc were procured from standard companies of high repute 
like Galaxo Laboratories, Merck, Qualigens, Sigma Chemical Company etc. similarly 
biomolecules like Taq DNA polymerase, proteinase K, dNTP’s, primers etc. were also 
obtained from standard companies like Fermentas, Biotools, Cinnagen etc. Kits used in 
the study were from Zymo Research Ltd. List of chemicals used along with their 
manufacturers is given in Appendix. 
 
3.1 CASES 
All the colorectal cancer patients that were operated in the Department of Surgery, 
Government S.M.H.S Hospital, Srinagar during the study period were included in the 
study irrespective of their age, gender and stage of the cancer 
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3.1.1 Inclusion criteria 
The diagnosis of colorectal cancer was based on the standard histopathological criteria. 
The criteria for including a subject as case in the study were: 
 All histopatholgically confirmed patients irrespective of cancer stage, age, 
gender. 
 Native patients belonging to Kashmir valley. 
3.1.2 Exclusion Criteria 
Under the following conditions the patients were not recruited in the study: 
 Patients who had received prior chemo or radiotherapy. 
 Patients not belonging to Kashmir valley. 
 Patients with genetic disorders like HNPCC/ APC. 
 Patients who suffered from any other kind of malignancy 
 
3.2 CONTROLS 
Resected colorectal samples from Department of Surgery, S.M.H.S Hospital including 
colorectal biopsies from Endoscopic section of S.M.H.S Hospital which were 
histopathologically confirmed as normal were taken as controls. 
3.2.1 Inclusion criteria 
 Native populace of the Kashmir valley. 
3.2.2 Exclusion criteria  
 Patients who suffered from any other kind of malignancy. 
 Patients not of Kashmiri origin. 
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3.3 COLLECTION OF TISSUE SAMPLES 
The carcinoma and control sample were obtained from the Department of Surgery and 
Endoscopic Section of Government S.M.H.S Hospital and were put in sterilized plastic 
vials (50 ml volume) containing 10 ml of normal saline and transported from the 
theatres to the laboratory on ice and stored at -80
 o
C for further analysis. 
3.4 GENETIC ANALYSIS 
 3.4.1 Extraction of genomic DNA 
For the isolation of genomic DNA, kit based method was used. The kit used was Quick- 
g DNA
TM
MiniPrep supplied by ZYMO RESEARCH. The protocol followed was as 
per kit. 
 25 to 50 mg of tissue was taken and the cells were mechanically homogenised in 
500 µl of Genomic Lysis Buffer (provided in the kit). 
  The lyaste was centrifuged at 10,000 g for 5 min. and the supernatant was 
transferred to Zymo-Spin
TM
Column in a Collection Tube and again centrifuged 
at 10,000 g for 1 min.  
 Flow through along with the Collection tube was discarded and the Zymo-
Spin
TM
 Column transferred to a new Collection tube and 200 µl of DNA Pre-
Wash Buffer (provided in the kit) was added to the tube and centrifuged at 
10,000 g for 1 min., this was followed by the addition of 500 µl of g- DNA 
Wash Buffer to the Zymo-Spin
TM
 Column and it was again centrifuged at 
10,000 g for 1 min.  
 The spin column was transferred to a clean micro centrifuge tube and DNA was 
eluted from it into the micro centrifuge tube by addition of 50 µl of DNA 
Elution Buffer (provided in the kit). 
The DNA eluted was stored at 4
0
C for a short time but the vials kept at -20
o
C for longer 
duration storage for further investigation. 
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 3.4.2 QUALITATIVE AND QUANTITATIVE ANALYSIS OF GENOMIC DNA  
The integrity of the genomic DNA was examined by gel electrophoresis using 1% 
agarose gel to which 10µl / 50ml (of gel solution) of fluorescent dye ethidium bromide 
was added during its cooling and then gel was cast and 20µl wells were cast into it by 
usage of suitable combs. 2µl of each DNA sample was mixed with 1µl of 1-X DNA 
loading dye (1-X loading dye consists of 4.16 mg bromophenol blue,4.16 mg xylene 
cyanol and 0.66g sucrose in 1 ml water) and was loaded onto the gel. Electric current 
was applied at 50 volt until DNA entered in to the gel and was raised to 70 volt for rest 
of the run. Run was stopped when the dye had travelled nearly 2/3rd of the gel. DNA in 
the gel was visualized with the help of Gel doc system (Alphaimager TM 2200, Alpha 
Innotech Corporation) under UV light and picture was captured by using CCD camera 
system (Figure 7). 
3.4.2.1 Quantitative Analysis 
The quantity of the DNA was determined by measuring optical density (OD) at 260nm 
and 280 nm by double beam spectrophotometer (Evolution 60S from Thermo Scientific) 
and the concentration was determined by using the fact that absorbance of 1 absorbance 
unit equates to 50µg/ cm
3
 and therefore, the concentration of DNA sample is given by 
the following equation 
DNA (µg/ml) = A260 x 50 x dilution factor 
 The ratio of 260/280 nm was calculated and the DNA samples for which the ratio was 
1.7-1.9 was considered for the future use. DNA was alliqouted into three to four tubes so 
as to protect damage from freeze thawing and stored in -20
o
C freezer for longer duration 
of time. 
3.5 DNA MODIFICATION (BISULFITE TREATMENT) 
Sodium bisulfite conversion will convert unmethylated cytosines to uracil and hence we 
are able to distinguish between the hypermethylated and non hypermethylated cytosine 
residues. DNA was modified by kit based method, the kit used was EZ DNA 
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Methylation
TM
 Kit supplied by ZYMO RESEARCH. The kit has > 99% conversion 
efficiency of converting non-methylated Cytosines residues into Uracil, and the modified 
DNA recovery from the kit is > 80%. In addition the methylation kit shares innovative in-
column desulphonation technology that eliminates otherwise cumbersome DNA 
precipitation steps while ensuring consistent results every time. The kit minimizes 
template degradation, loss of DNA during treatment and clean-up, and to provide 
complete conversion of unmethylated cytosines. Recovered DNA is ideal for PCR 
amplification. The kit protocol was followed. 
 500-1000ng of above isolated DNA samples were taken in different Eppendorf 
tubes. 
 5 µl of M-Dilution Buffer (provided in the kit) was added to each sample and 
final volume was made to 50 µl with distilled water. 
 100µl CT-Conversion Reagent (provided in the kit) was added to each tube and 
all tubes were placed in dark at 50
o
C - 55
o
C for 12-16 hrs. 
 After that all samples were placed on ice for 5-10 mins. 
 400 µl of M-binding buffer (provided in the kit) was added to the Zymo-
Spin
TM
 IC Column (provided in the kit) and the column was placed into a 
provided Collection Tube. 
 Sample from step 4 was loaded into the Zymo-SpinTM IC Column containing 
M-binding buffer. Cap was closed and mixing done by inverting the column 
several times. 
 Centrifuge at full speed (≥10,000 g) for 30 seconds. Flow-through discarded. 
 100 µl of M-Wash Buffer (provided in the kit) was added to the column 
followed by centrifugation at full speed for 30 seconds. 
 200 µl of M-Desulphonation Buffer (provided in the kit) was added to the 
column and it was allowed to stand at room temperature (20
0
C-30
0
C) for 15-20 
minutes. After the incubation, it was centrifuged at full speed for 30 seconds. 
 200 µl of M-Wash Buffer was added to the column, and centrifuged at full 
speed for 30 seconds; another 200 µl of M-Wash Buffer was added and again 
centrifuged for additional 30 seconds. 
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Figure 7: Representative gel picture showing the integrity of the genomic DNA      
                on 1.0% agarose. Lane 1 to 7 contains the genomic DNA isolated from    
                the tissue samples of colorectal cancer cases. 
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 Column was placed into a 1.5 ml micro centrifuge tube and of 15µl of M-
Elution Buffer (provided in the kit) was directly added to the column matrix, 
and then it was centrifuged for 30 seconds at full speed to elute the DNA. 
The DNA obtained is ready for immediate analysis or can be stored at or below -20
0
C 
for later use. 
3.6 METHYL SPECFIC POLYMERASE CHAIN REACTION (MSP)  
MSP is a novel, sensitive and inexpensive way for detection of hypermethylation in CpG 
islands of DNA (Herman et al., 1996). This approach allows the determination of 
methylation patterns from very small samples of DNA. The principle of this PCR method 
is the is a bisulfite conversion of unmethylated cytosines into uracil in the  CpG islands of 
DNA and then the amplification of the bisulfite treated DNA of the same gene by 
different primer sequence; one for hypermethylated version of the gene and one for the 
non-methylated version of the same gene. Thus by visualising the PCR product it can 
easily be determined whether amplification is by hypermethylated or non-methylted 
primers, thus determine whether our CpG’s were hypermethylated or non methylated. 
As described earlier PCR was carried out using methyl specific PCR (MSP) method. The 
modified DNA is taken into two PCR vials in equal quantity and same amount of all 
reagents (Table 2) is added to both the vials except in one vial methylated primers and in 
other non-methylated primers are used (Table 3). 
PCR amplification was achieved using a Thermal cycler (Gradient thermal cycler from 
EPPENDORF MASTERCYCLER PRO). Reactions were hot-started at 95
o
C for 5 min, 
followed by addition of Taq. Polymerase, followed by 35 cycles of melting (95
o
C for 45 
sec.), annealing (59
0
C for  45 sec.) and extension (72
o
C for  45 sec.) and by final 
extension step at 72
o
C for 4 min ( Table 4). 
Controls without DNA were performed for each set of PCRs along with both positive and 
negative controls. Each PCR reaction (10 μl) was directly loaded onto 4 % agarose gel, 
stained with ethidium bromide, and visualized under UV illumination. 
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Table 2: Volume and concentrations of different reagents used in PCR. 
 
Reagent Volume 
1 X Taq buffer 2.5 µl 
dNTPs (1.25mM/ L) 1.25 µl 
Forward primer (150 ng/ reaction) 1µl 
Reverse primer (150 ng/ reaction) 1 µl 
Template DNA(50 ng/ reaction) 1.25 µl 
Taq DNA Polymerase( 5U/ µl ) 0.2 µl 
De ionised water 17.8 µl 
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Table 3: Primer pairs used for amplification of the DNA Samples 
 ( Esteller et al., 1999 a ). 
 
 
Nature of Sequence Primer sequence 
 
UNMETHYLATED 
PRIMER  
Forward 
primer 
5’-TTTGTGTTTTGATGTTTGTAGGTTTTTGT- 3’ 
Reverse 
primer 
5’-AACTCCACACTCTTCCAAAAACAAAACA- 3’ 
 
METHYLATED 
PRIMER  
Forward 
primer 
5’-TTTCGACGTTCGTAGGTTTTCGC- 3’ 
Reverse 
primer 
5’-GCACTCTTCCGAAAACGAAACG- 3’ 
 
 
 
 
 
 
 
 
 
                                                                                                Materials and Methods 
55 
 
Table 4: Thermal cycling conditions for Methyl Specific Poplmerase Chain 
Reaction (MSP). 
 
Steps 
 
Temperature
0
C Time Number of 
cycles 
1. Hot-Start 95 5 min 1 
2.  Denaturation 95 45 sec  
35 
3. Annealing 59 45 sec 
4. Extension 72 45 sec 
5. Final extension 72 4 min 1 
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Universal Methylated Human DNA Standard and Control with primers (ZYMO 
RESEARCH) were used as positive control and normal lymphocyte DNA as negative 
control. 
The amplified DNA are of different base pairs in length the methylated band is 81 bp and 
the unmethylatd band is 93 bp and this difference in the size of the amplified DNA 
allowed them to be visually differentiated in presence of a 20- 1000 bp DNA ladder run 
parallel to the amplified PCR products on 4% ethidium bormide pre-loaded agarose gel 
 
3.7 STATISTICAL ANALYSIS 
The χ2-test with Odds ratio was used to examine the differences in the distribution of 
genotypes between cases and controls and Fishers exact test was used in case of 
studying the male and female groups as cell frequency was less than 5 in some cells.  
ORs with 95% CIs were computed using unconditional logistic regression using Graph 
Pad Prism Software Version 5.0 by Graph Pad Software 2236, Avenida de la Playa, La 
Jolla, CA 92037, USA. 
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4.1. General characteristics of Study Population 
In the present study, 50 colorectal tissue samples were taken from colorectal cancer 
patients of Kashmir valley and 20 histopathologically confirmed normal tissues 
samples taken as controls General characteristics of the colorectal cancer patients 
were recorded in the detailed case history. In the study the case vs. control effect 
and gender effect of promoter hypermethylation of MGMT gene was studied. The 
data obtained is depicted in the table 5. 
 
4.2 ANALYSIS OF MGMT GENE PROMOTER HYPERMETHYLATION 
Analysis of the MGMT gene promoter hypermethylation was conducted using 
Methyl specific PCR (MSP) reaction. The amplicons were analysed on 4% agarose 
gel. Amplification was carried out using PCR-Hot Start method; the method 
involves heating the PCR mix without Taq DNA Polymerase upto 95
o
C for 5 min. 
and then adding Taq DNA Polymerase to it. This decreases the non specific 
amplifications. The amplicon of methylated and non methylated primers is of 
different sizes i.e. 81 and 93 bp respectively and is depicted in table 6. 
Figures 8 and 10 represent the gel images of cases and controls respectively. 
 
4.2.1 General overview 
Out of total of total 70 specimens studied of which 50 were cases and 20 controls. 
The information generated is depicted in figure 13. 
To further analyse the data and to study whether gender has any role in promoter 
hypermethylation of MGMT gene, we split the cases and controls into two groups 
i.e. males and females and accordingly interpreted the promoter hypermethylation 
and non hypermethylation in these groups which is depicted in figure 14-18. 
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Table 5:-Gender study 
 
 Characteristics 
Cases 
(50) 
Controls 
(20) 
Gender 
        Male 29 10 
Female 21 10 
 
 
Table 6: Different lengths of fragments obtained in PCR 
 
Nature of 
Sequence 
Primer sequence Size of 
Amplicon 
 
UNMETHYLATED 
PRIMER 
Forward 
primer 
5’-
TTTGTGTTTTGATGTTTGTAGGTT
TTTGT- 3’ 
 
93 bp 
Reverse 
primer 
5’-
AACTCCACACTCTTCCAAAAACA
AAACA- 3’ 
 
METHYLATED 
PRIMER 
Forward 
primer 
5’-
TTTCGACGTTCGTAGGTTTTCGC- 
3’ 
 
81 bp 
Reverse 
primer 
5’-
GCACTCTTCCGAAAACGAAACG- 
3’ 
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Figure 8: The cancer DNA samples amplified by MSP on 4% Agarose 
Gel stained with Ethidium Bromide. 
 
Lane1        Positive control (Universal methylated human DNA) 81bp 
Lane2 
CRC 5 
Amplification by methylated primer 
CRC sample 
promoter is 
hypermethylated 
Lane3 Amplification by unmethylated primer 
Lane4 
CRC 25 
Amplification by methylated primer 
CRC sample 
promoter is 
hypermethylated 
Lane5 Amplification by unmethylated primer 
Lane6 
CRC 45 
Amplification by methylated primer 
CRC sample 
promoter is 
hypermethylated 
Lane7 Amplification by unmethylated primer 
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Figure 9: The cancer DNA samples amplified  by MSP run along with 
Molecular Size DNA Ladder on 4% Agarose Gel stained with Ethidium 
Bromide. 
 
 
lane 1 Molecular Size Marker 
Lane 2 MSP Amplicon of Sample CRC 5 
Lane 3 MSP Amplicon of Sample CRC 24 
Lane 4 MSP Amplicon of Sample CRC 36 
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Figure 10: The Normal DNA samples amplified by MSP on 4% 
Agarose Gel stained with Ethidium Bromide. 
Lane 1 
Normal 1 
Amplification by unmethylated primer 
Normal sample promoter is  
not hypermethylated 
Lane 2 
No Amplification by methylated 
primer 
Lane 3 
Normal 6 
Amplification by unmethylated primer 
Normal sample promoter is  
not hypermethylated 
Lane 4 
No Amplification by methylated 
primer 
Lane 5 
Normal 15 
Amplification by unmethylated primer 
Normal sample promoter is  
not hypermethylated 
Lane 6 
No Amplification by methylated 
primer 
Lane 7 
NEGATIVE 
CONTROL 
Amplification by unmethylated primer 
NEGATIVE CONTROL not 
hypermethylated 
Lane 8 
No Amplification by methylated 
primer 
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Figure 11: The Normal DNA samples amplified  by MSP run along 
with Molecular Size DNA Ladder on 4% Agarose Gel stained with Ethidium 
Bromide. 
 
lane 1 Molecular Size Marker 
Lane 2 MSP Amplicon of Sample  Normal  5 
Lane 3 MSP Amplicon of Sample Normal 9 
Lane 4 MSP Amplicon of Sample Normal 13 
Lane 5 MSP Amplicon of Sample Normal 19 
Lane 6 MSP Amplicon of Sample Normal 20 
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Figure 12:  The Normal and cancer DNA samples amplified by MSP 4% 
Agarose Gel stained with Ethidium Bromide. 
 
Lane 1               Positive control 81bp 
Lane 2               Negative control 93bp 
Lane 3 
CRC 9 
Amplification by methylated primer CRC sample 
promoter is 
hypermethylated Lane 4 Amplification by unmethylated primer 
Lane 5 
CRC 19 
Amplification by methylated primer CRC sample 
promoter is 
hypermethylated Lane 6 Amplification by unmethylated primer 
Lane 7 
Normal 5 
Amplification by methylated primer NORMAL sample 
promoter is 
hypermethylated Lane 8 Amplification by unmethylated primer 
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Figure 13: Bar diagram showing Case Vs Control data w.r.t promoter 
hypermethylation status of MGMT gene 
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Figure 14: Bar diagram showing Male Vs Female data 
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Figure 15: Bar diagram showing Hypermethylation status of promoter of 
MGMT gene of Cases Vs Control 
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Figure 16: Bar diagram showing Non- Hypermethylation status of promoter 
of MGMT gene Cases Vs Control 
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Figure 17: Bar diagram showing hypermethylation Vs non hypermethylation 
in both Case Vs Control data for Males 
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Figure 18: Bar diagram showing hypermethylation Vs non hypermethylation 
in both Cases and Control data in Females 
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4.2.1.1. Cases 
In the present study 50 histopathologically confirmed cancer cases belonging to 
Kashmir division were analysed for promoter hypermetylation of MGMT gene 
using Methyl Specific PCR. The distribution of the samples as per their sex and 
status of promoter hypermethylation of the MGMT gene has been depicted in table 
7,8 and 9. In determining the promoter hypermethylation status of the cases it was 
observed that out of 50 cases 27 (54%) had promoter hypermethylation of MGMT 
gene and 23 cases (46%) did not have promoter hypermethylation of MGMT 
gene(Table 7). Out of 50 cases 29 were males and 21 were females which 
correspond to 58% males and 42% females respectively. The number of samples 
having promoter hypermethylation in the MGMT gene in males came out to be 21 
out of the 29 case samples, which corresponds to 72.41% promoter 
hypermethylation (Table 8) and similarly in females the numbers of cases having 
promoter hypermethylation of MGMT gene came out to be 6 out of 21 cases which 
correspond to 28.57% promoter hypermethylation (Table 9). 
 
4.2.1.2. Controls 
Twenty histopathologically normal controls were taken from Department of 
Surgery, including biopsies from Endoscopic Section and were screened for the 
promoter hypermethylation in the MGMT gene. Out of twenty controls ten were 
males and ten were females. Both were taken in equal numbers which corresponds 
to 50 % respectively. In determining the promoter hypermethylation status of the 
controls it was observed that out of 20 control 4 (20%) had promoter 
hypermethylation of MGMT gene and 16 cases (80%) did not have promoter 
hypermethylation of MGMT gene (Table 10). Out of 10 male controls 3 were 
having promoter hypermethylation in the MGMT gene which correspond to 30% 
promoter hypermethylation (Table 11) and out of 10 female control specimen just 1 
came out to be positive for promoter hypermethylation in the MGMT gene which 
correspond to just 10% promoter hypermethylation (Table 12). 
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Table 7: Promoter Hypermethylation Vs Non Hypermethylation in Cases.  
PARAMETER NUMBER  
HYPERMETHYLATION 
 
NON- 
HYPERMETHYLATION 
27 (54 %) 
 
23 (46 %) 
 
      50 CASES 
 
 
Table 8: Promoter Hypermethylation Vs Non Hypermethylation in Male 
Cases. 
MALES (29)   {CASES 50} 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATION 21 72.41 % (21/29) 
NON-
HYPERMETHYLATED 
8 27.58 % (8/29) 
 
 
Table 9: Promoter Hypermethylation Vs Non Hypermethylation in Female 
Cases. 
FEMALES (21)    {CASES 50} 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATION 6 28.57 % (6/21) 
NON 
HYOERMETHYLATED 
15 71.14 % (15/21) 
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Table 10: Promoter Hypermethylation Vs Non Hypermethylation in Controls. 
 PARAMETER                                 NUMBER 
HYPERMETHYLATION 
 
NON- 
HYPERMETHYLATION 
4 (20%) 
 
16 (80%) 
 
      20 CONTROLS 
 
 
Table 11: Promoter Hypermethylation Vs Non Hypermethylation in Male 
Controls. 
MALES (10)     {CONTROLS (20)} 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATION 3 30 % (3/10) 
NON 
HYOERMETHYLATED 
7 70 % (7/10) 
 
 
Table 12: Promoter Hypermethylation Vs Non Hypermethylation in Female 
Controls. 
FEMALES (10)   {CONTROLS (20)} 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATION 
NON 
HYOERMETHYLATED 
1 
9 
10 % (1/10) 
90 % (9/10) 
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4.3. DESCRIPTIVE EPIDEMIOLOGY 
As several studies have revealed that colorectal carcinogenesis is the result of the 
contribution of various factors such as environmental, dietary and genetic and since 
there is a high incidence of gastrointestinal malignancies in Kashmir, the current 
study was aimed at understanding the relationship if any between high incidence of 
colorectal cancer and the promoter hypermethylation of MGMT gene in Kashmiri 
Population.  
On analyzing the data it comes out that out of 50 colorectal cancer patients 
registered, 29 were males and 21 were females hence the ratio comes out to be 
1.38. Of all the ten districts highest number of colorectal cases turned out from 
Srinagar and Budgam districts of Kashmir valley which are the main urbanized 
towns of the valley hence indicating the role of urban lifestyle in the development 
of this disease. Besides this study also reveals that male gender has greater 
percentage of MGMT promoter hypermethylation as compared to females in 
Kashmiri population. 
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Colorectal cancer (CRC), commonly known as bowel cancer is the third most 
common cause of cancer-related death in the western world. The annual incidence of 
CRC worldwide has been estimated to be at least half a million (Kemp et al., 2004). 
It is a commonly diagnosed cancer in both men and women. In 2008, an estimated 
148,810 new cases will be diagnosed, and 49,960 deaths from colorectal cancer will 
occur (ACS, 2008). Most colorectal cancers (CRC) develop through multiple 
mutations in the normal colonic mucosa, and evolve through the adenoma-carcinoma 
sequence (Kinzler and Vogelstein, 1996; Fearon and Vogelstein, 1990). The 
development of CRC is a multi-step process, which can arise due to cumulative 
effect of mutations in various different oncogenes, tumor suppressor genes and/or 
from epigenetic changes in DNA (Mustafa et al., 2007). Recent progresses made in 
the field of molecular biology have shed a light on the different alternative pathways 
involved in the colorectal carcinogenesis and more importantly cross talk among 
these pathways (Risques et al., 2003; Takayama et al., 2006).Various endogenous 
and exogenous agents from environmental exposures are constantly damaging DNA, 
and in combination with low DNA repair capacity this have been interpreted as 
increasing the likelihood of cancer development (Wei et al., 1995; Wei et al., 1996; 
Cheng et al., 1998; Shi et al., 2004).  
Colon being the waste processor of our body is in particular exposed to a wide array 
of endo as well as exogenous chemicals. Normally detox reactions are going on in 
our body at all the times and sometimes these lead to the production of certain 
harmful chemical compounds eg. Lithocholic acid (LCA) (component of bile acids) 
is implicated in human and experimental animal carcinogenesis. Its effect on 
apoptosis and proliferation of the colonic epithelium was studied in a 1,2-
dimethylhydrazine (DMH)-induced murine carcinogenesis model (Kazoni et al., 
2000). On the other hand we eat a variety of compounds both natural and man made 
and these contain a cocktail of chemicals which have a potential of acting as 
carcinogens like mono sodium glutamate, poly aromatic hydrocarbons, 
nitrosoamines (Siddiqi et al., 1992). As colon is always in direct contact with these 
types of chemicals it can be understood as to why there is a high occurrence of 
colorectal cancer in general population.  
 
                                                                                                                  Discussion 
75 
 
The current study was aimed at understanding  
 
 The promoter hypermethylationstatuses of MGMT gene of colorectal 
subjects of Kashmiri origin subjects and their corelation histopathologically 
confirmed controls. 
 Further, analysis of role of sex if any in the promoter hypermethylation of 
MGMT gene. 
 
The male to female ratio of the cancer in study was 1.38. Highest number of 
colorectal cases turned out to be from Srinagar and Budgam districts which are the 
main urbanized towns of the Valley implicating a role of urban lifestyle in etiology 
of this cancer, which can be further evaluated in a detailed study. The epi-genetic 
analysis of the cases and controls revealed that unlike other high risk regions, 
Kashmiri population has a different hypermethylation profile of MGMT promoter. 
Analysed data showed was found that 54% (27/50) of the cases had MGMT 
promoter hypermethylation as compared to 20% (4/20) in controls  and was 
statistically significant with a three-fold increase in risk of developing colorectal 
cancer (O.R = 4.69, 95% C.I = 1.37 – 16.05, P = 0.015) by using χ2 test with Odds 
Ratio. This clearly indicates that promoter hypermethylation may have a link with 
etiology of colorectal cancer in this particular ethnic and geographical location. This 
can be taken into account in establishing a DNA hypermethylome as a marker for 
colorectal cancer if feasible. 
Besides this, study was carried to analyze the effect of gender biasing w.r.t the 
promoter hypermethylation of MGMT gene.  This study revealed that the male 
gender has generally higher incidence of MGMT promoter hypermethylation 
(72.41% vs. 30%) as compared to controls, with a statistically significant results and 
even more than three-fold increase in risk of developing this particular type of cancer 
(O.R = 6.13, 95% C.I = 1.26 – 29.71, P = 0.026) by using Fisher’s Exact Test. As in 
case of the females, it was found that though percentage of promoter 
hypermethylation of MGMT gene of female cases was more as compared to female 
controls (28.57% vs. 10%), the data was not statistically significant (O.R = 3.6, 95% 
C.I = 0.37 – 34.93, P = 0.37) using Fisher’s Exact test. Similarly when data was 
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analyzed for the male verses female cases of promoter hypermethylation of MGMT 
gene the results were statistically significant (O.R = 6.563, 95% C.I = 1.882 - 22.82, 
P = 0.0037) using Fisher’s Exact Test. 
In summary, this is the first observational study to examine the status of promoter 
hypermethylation of MGMT gene in colorectal cancer patients of Kashmir valley. 
The study revealed that urban life style may have a role in the development of this 
particular type of cancer as majority of the cases were from the main urban cities of 
the Kashmir valley i.e. Srinagar and Budgam. Data indicates that MGMT aberrant 
methylation may play an important role in colorectal cancer development. It also 
clearly demonstrates that hypermethylation of MGMT gene can be designated as 
epigenetic biomarker for the early diagnosis and better prognosis of colorectal 
cancer. The study also reveals that males have higher incidence of colorectal cancer 
as compared to females and also that the promoter hypermethyltion of MGMT gene 
is more frequent in male colorectal patients as compared to the females.  
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Appendix 
 
CHEMICALS AND REAGENTS 
CHEMICALS 
Chemical Name Company 
Absolute ethanol BENGAL CHEMICALS 
Acetone GALAXO LABORATORIES 
Agarose MP BIOMEDICALS 
Ammonium  chloride BDH 
Ammonium acetate BDH 
Bromophenol blue SARABHAI  M  CHEMICALS 
Chloroform THOMAS BAKERS 
De Ionized water ALFA LABORATORIES 
Ethidium bromide SRL 
Ethyl acetate MERCK 
Ethylene diamine tetra acetate (EDTA) LOBA CHEMIE 
Formaldehyde GALAXO LABORATORIES 
Glacial Acetic acid MERCK 
Hydrochloric acid S D FINE CHEMICALS 
Hydrogen peroxide MERCK 
8-Hydroxyquinoline CDH 
Isoamyl alcohol BDH 
Isopropanol THOMAS BAKERS 
Magnesium chloride MERCK 
Methanol SARABHAI  M  CHEMICALS 
Phenol  SRL 
Potassium acetate QUALIGENS 
Potassium bicarbonate QUALIGENS 
Potassium chloride LOBA- CHEMIE 
Potassium hydroxide S D FINE CHEMICALS 
2-Propanol MERCK 
Sodium acetate SARABHAI  M  CHEMICALS 
Sodium azide LOBA CHEMIE 
Sodiun bisulphate LOBA CHEMIE 
Sodium carbonate FIZMERCK 
Sodium chloride MERCK 
Sodium dodecyl sulphate MP BIOMEDICALS 
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Sodium hydroxide HIMEDIA 
Sodium hydrogen carbonate LOBA- CHEMIE 
Sodium phosphate dibasic LOBA- CHEMIE 
Sodiun thiosulfate LOBA CHEMIE 
Sucrose QUALIGENS 
Sulfuric acid MERCK 
TE buffer SRL 
Tris base SIGMA CHEMICAL COMPANY 
Tris HCL HIMEDIA 
Triton X 100 S D FINE CHEMICALS 
 
 
 
ENZYMES 
 
Taq polymerase FERMENTAS /  BIOTOOLS 
Proteinase K ZYMO RESEARCH 
 
 
 
MISCELLANEOUS  MATERIAL 
 
20- 1000bp DNA ladder SIGMA ALDRICH (D7807) 
 
 
 
PCR  REAGENTS 
 
10 X Buffer (with Mgcl2) BIOTOOLS 
dNTPs  CINNAGEN 
Primers (methylated and  unmethylated) GENESCRIPT 
Universal Methylated Human DNA 
Standard and Control with primers 
ZYMO RESEARCH 
 
 
DNA Isolation: 
DNA was isolated by kit based method. The kit used was Quick- g DNA
TM 
MiniPrep 
supplied by ZYMO RESEARCH. Kit protocol was followed for DNA isolation. 
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DNA storage buffer: 
0.5 M EDTA        0.01 ml 
1 M Tris        0.5 ml 
Final volume was made 50 ml with sterile distilled water. 
 
DNA Bisulfite Modification: 
DNA was modified by kit based method, the kit used was EZ DNA Methylation
TM
 Kit 
supplied by ZYMO RESEARCH. Kit protocol was followed for bisulfite modification 
of isolated DNA. 
 
REAGENTS FOR AGAROSE GEL ELECTROPHORESIS: 
Agrose 1 % / 2%:                  
Agarose        0.5g  / 1.0g 
Buffer         50ml 
Ethidium bromide       10µl 
Agarose was dissolved in a buffer and heated till a clear solution is formed. Ethidium 
bromide was then added to the solution during its cooling just before being poured into 
the casting tray. 
 
Bromophenol Blue: 
Bromophenol Blue       0.4g 
Sucrose        20.0g 
Bromophenol blue was dissolved in 100ml of distilled water. 
From the above stock solution 31.25ml was taken and sucrose was added. Final volume 
was made 50ml with distilled water. 
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Ethidium Bromide 
Ethidium bromide       10mg 
Ethidium Bromide was dissolved in 1ml of distilled water. The solution was stored in a 
dark bottle at 4˚C. 
 
50-X TAE (pH 8.0) STOCK SOLUTION: 
Tris base        242g 
0.5M EDTA        100ml 
Glacial acetic acid       57.1ml 
Final volume was made 1000ml with distilled water. This is stock solution. 
 
1-X  TAE (pH 8.0) WORKING SOLUTION: 
50-X  TAE        20ml 
Final volume was made 1000ml with distilled water. 
 
Reagents for PCR: 
Stock 
Deoxyribose Nucleotide Triphosphate (dNTP) 100mM each  dATP,  dGTP,  dCTP  and 
dTTP. 
Taq polymerase (5U/µl) 
10X Taq buffer  (16 mmol/L Ammonium sulphate; 67 mM/L Tris- HCL, pH 8.8; 10 
mM/L  2-Mercaptoethanol); 6.7 mM/ L MgCl2) 
Primers: 100pM in sterile deionised water (Genescript)  
20- 1000bp DNA ladder (0.5µg/µl) 
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Prevalence of Promoterhypermethylation of MGMT Gene in Colorectal Cancer 
Patients of Kashmir Valley. 
Colorectal cancer, one of the most aggressive cancers, occurs with a high incidence 
in most countries. Colorectal cancer (CRC) is one of the leading malignancies 
worldwide. Cancer development and progression is dictated by series of alterations 
in genes such as tumor suppressor genes, DNA repair genes, oncogenes and others. 
In this study, efforts were made to identify promoter hypermethylation of CpG 
islands of MGMT gene in CRC patients among the Kashmiri population. 
Methylation status of CpG islands in the promoter region of MGMT gene in 
colorectal cancers and normal corresponding colonic mucosa was analysed. Fresh 
tissue samples were obtained from 50 patients (age of 21 to 81 years) undergoing 
resective surgery for CRC with primary colorectal adenocarcinonia and 
corresponding histopathologically normal tissues. Methylation-specific polymerase 
chain reaction (MSP) was used for analysis of the promoter methylation status of 
MGMT gene. The male to female ratio of the disease came out to be 1.38. The 
epigenetic analysis of the cases and controls revealed that unlike other high risk 
regions, Kashmiri population has a different hypermethylation profile of MGMT 
gene promoter hypermethylation. The frequency of cases with MGMT  promoter 
hypermethylation was more as compared to controls (54% vs. 20%) and was 
statistically significant (O.R = 4.69, 95% C.I = 1.37 – 16.05, P = 0.015) using χ2 test 
with Odds Ratio. It was also found that the frequency of male cases with promoter 
hypermethylation of MGMT gene was more as seen against male controls (72.41% 
vs. 30%), which also showed statistically significant results (O.R = 6.13, 95% C.I = 
1.26 – 29.71, P = 0.026) using Fisher’s Exact test, though the frequency of promoter  
hypermethylation of MGMT  gene of female cases was more as compared to female 
controls (28.57% vs. 10%), the data was found not to be statistically significant (O.R 
= 3.6, 95% C.I = 0.37 – 34.93, P = 0.37) using Fisher’s Exact. While for the male 
verses female cases of promoter hypermethylation of MGMT gene the results were 
statistically significant (O.R = 6.563, 95% C.I = 1.882 - 22.82, P = 0.0037) using 
Fisher’s Exact Test. 
In this study it was concluded that male gender is generally associated with higher 
methylation levels for most CpG islands hypermethylation of MGMT gene in normal 
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as well as cancerous colonic mucosa. The results indicate that MGMT aberrant 
methylation may play an important role in colorectal cancer. This study clearly 
demonstrates that promoter hypermethylation of MGMT gene can be designated as 
epigenetic biomarker for early diagnosis and better prognosis of the disease. 
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Colorectal cancer (CRC), also called colon cancer or large bowel cancer includes 
cancerous growths in the colon, rectum and appendix. With 655,000 deaths worldwide 
per year, it is the fifth most common form of cancer in the United States and the third 
leading cause of cancer-related death in the Western world (WHO, 2006; NCI, 2009). 
Colorectal cancer being the commonest cancer is the major cause of mortality and 
morbidity worldwide, there are nearly one million new cases of colorectal cancer 
diagnosed world-wide each year and half a million deaths (Boyle and Elena, 2002). It is 
a commonly diagnosed cancer in both men and women. In 2008, about 148, 810 new 
cases were diagnosed in U.S, and almost 49,960 deaths from colorectal cancer were 
speculated (American Cancer Society, 2008). The incidence of this malignancy shows 
considerable variation among racially or ethnically defined populations in 
multiracial/ethnic countries. Kashmir has been reported by now as a high-incidence area 
of GIT cancers (Shah and Jan, 1990; Salam et al., 2009; Mir et al., 2005).Colorectal 
Cancer in Kashmir valley is the third most common GIT cancer after esophageal and 
gastric cancer as per reports (Sameer et al., 2009).The development of CRC is a 
multistep process, which can arise due to the cumulative effect of mutations in various 
different proto-oncogenes, tumor suppressor genes, and/or from epigenetic changes in 
DNA (Mustafa et al.,2007; Vogelstein et al., 1988; Fearon and Vogelstein, 1990). 
Colorectal cancer is a disease originating from the epithelial cells lining the colon or 
rectum of the gastrointestinal tract, as a result of mutations to some of the genes. Some 
of the mutations are inherited, and others are acquired (Ionov et al., 1993; Chakravarthi 
et al., 1999). Some genes are oncogenes -- they are over expressed in colorectal 
cancer.RAS, RAF, and PI3K, which normally encourage the cell to divide in response to 
growth factors, can become mutated with mutations that make them over signal the cell. 
There are two major mechanisms of gene inactivation. One is the genetic mechanism, 
i.e. the aberration of DNA structure such as homozygous deletion or intragenic mutation 
resulting in the gene inactivation. The other is the epigenetic mechanism, i.e., the 
methylation of the position 5 of cytosine (C) leading to the lack of gene expression, 
while the structure and the product of the gene remain unchanged. In higher order 
eukaryotes, DNA is methylated only at cytosines located 5’ to guanosine in the CpG 
dinucleotide. This modification has important regulatory effects on gene expression, 
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especially when involving CpG rich areas known as CpG islands, located in the 
promoter region of many genes. While almost all gene-associated islands are protected 
from methylation on autosomal chromosomes, extensive methylation of CpG islands has 
been associated with transcriptional inactivation of selected imprinted genes and the 
genes on inactivated X chromosome of females. Aberrant methylation of normally 
unmethylated CpG islands has been associated with transcription inactivation of gene 
(Zingg and Jones., 1997). It is a complex process catalyzed by DNA methyltransferase 
(DNMTs).The methyl group is donated by the universal methyl donor s-adenosyl L -
methionine. 
Unmethylated CpGs are grouped in clusters called "CpG islands" that are present in the 
5' regulatory regions of many genes. In many disease processes such as cancer, gene 
promoter CpG islands acquire abnormal hypermethylation, which results in 
transcriptional silencing (Jaenisch and Bird, 2003). DNA methylation may affect the 
transcription of genes in two ways. First, the methylation of DNA may itself physically 
impede the binding of transcriptional proteins to the gene and secondly, and likely more 
important, methylated DNA may be bound by proteins known as methyl-CpG-binding 
domain proteins (MBDs). MBD proteins then recruit additional proteins to the locus, 
such as histone deacetylases and other chromatin remodeling proteins that can modify 
histones, thereby forming compact, inactive chromatin termed silent chromatin. 
Promoter hypermethylation is one of the hallmarks of carcinogenesis associated with 
transcriptional silencing and loss of expression of genes encoding for diverse cellular 
pathways (Esteller , 2007). Most of the evidence exists for tumor suppressor genes (Issa, 
2004; Laird,  2005). Hypermethylation leads to silencing of gene transcription through a 
complex process involving chromatin condensation and histone deacetylation (Jones et 
al., 1998; Wade et al., 1999). 
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1.2 MGMT 
O
6
-methylguanine-DNA methyltransferase (MGMT) is a ubiquitous DNA repair protein 
that removes mutagenic and cytotoxic adducts from the O
6
-guanine in DNA, the 
preferred point of attack of many carcinogens and alkylating chemotherapeutic agents 
(Esteller, 2003; Esteller and Hermann, 2004). Methylation of CpG islands within the 
promoter region may lead to silencing of gene transcription through a complex process 
involving chromatin condensation and histone deacetylation (Jones et al., 1998; Wade et 
al., 1999). Epigenetic silencing through DNA methylation can begin very early in tumor 
progression and may affect multiple genes involved in different cellular pathways, 
including cell cycle control, DNA repair and many others (Baylin et al., 1998; Baylin et 
al., 2001). Epigenetic modification can cause inactivation of DNA repair genes, such as 
O6-methylguanine DNA methyltransferase (MGMT) (Esteller et al., 1999 a).Human 
MGMT gene possess a CpG island in the promoter region (Harris et al., 1991) and it has 
been reported that the methylation of discrete regions of the MGMT CpG island is 
associated with the silencing of the gene in cell lines (Costello et al., 1996; Qian and 
Brent, 1997; Watts et al., 1997). Methylation of MGMT promoter region in colorectal 
cancer tissue has been known and documented in several independent studies (Shen et 
al., 2005; Suehiro et al., 2008). MGMT (O
6
-methylguanine DNA methyltransferase) is a 
DNA repair enzyme and is involved in the removal of alkyl adducts from the O6 
position of guanine. These adducts can be mutagenic and cytotoxic (WHO, 2006). The 
persistence of O
6
 methyl guanine adducts, resulting from alkylating agents, may cause 
DNA polymerase to misread the base pairing because of the altered hydrogen-bonding 
properties of a base that contains an additional methyl or ethyl group. Thus, O
6
-
methylguanine is read as an adenine and mis-pairs with thymine (Horsfall et al., 1990). 
Supporting this data, the most common mutations caused by alkylating agents are G:C 
to A:T transitions (Horsfall et al., 1990), exemplified in the frequent generation of G to 
A transitions in the oncogene k-Ras when the carcinogen N-methyl nitrosourea (that 
forms O
6
-methylguanine adducts) is used in experimentally induced tumor systems 
(Mitra et al., 1989). Avoidance of the mutagenic effect is directly related to the presence 
of a functional MGMT protein (Pegg et al., 1995). MGMT removes alkyl groups by 
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transferring the alkyl group from the O
6
-guanine in DNA to an active cytosine within its 
own sequence in a reaction that inactivates one MGMT molecule for each lesion 
repaired (Pegg, 1990).  Thus, the ability of a cell to withstand such damage is directly 
related to the number of MGMT molecules it contains and to the rate of de novo 
synthesis of MGMT. The amounts of MGMT protein differ according to cellular type 
(Gerson et al., 1986; Citron et al., 1991) and are decreased in some tumors, with respect 
to their normal tissue counterpart (Citron et al., 1991; Citron et al., 1992). In vitro 
assays show that endogenous MGMT expression protects mammalian cell lines from 
spontaneous G: C to A: T transitions in the APRT gene (Aquilina et al., 1992). Animal 
models also show that transgenic mice over expressing MGMT are protected against O
6
 
methyl guanine-DNA adducts caused by methyl nitrosourea (Dumenco et al., 1993) and 
against G to A mutations in K-ras in aberrant colorectal crypt foci and lung tumors 
(Zaidi et al., 1995; Liu et al., 1999). It has recently shown that MGMT is 
transcriptionally silenced by promoter hypermethylation in a wide spectrum of human 
neoplasms (Esteller et al., 1999 a) and provided the first evidence in human primary 
tumors of the linkage between MGMT epigenetic inactivation and the appearance of G 
to A mutations in K-ras (Esteller et al., 2000; Nagasaka et al., 2003) found that 
methylated MGMT was significantly related to lower risk of recurrence in colorectal 
cancer. 
In the case of colorectal tumors, the pro-mutagenic lesion affecting the O
6
-guanine can 
be caused by alkylating agents provided from dietary nitrates that are reduced in the 
proximal colon by bacteria or by nitrosation of amines and amides derived from protein 
catabolism (Bartsch et al., 2004; Rowland et al., 1991; Ward et al., 1989). So the main 
aim of the study was: 
 To study the promoter hypermethylation of MGMT gene in colorectal patients 
of Kashmir that may help in early diagnosis and better prognosis of the disease 
so that further preventive measures could be taken.  
